id	sid	tid	token	lemma	pos
cord-302018-3rlya16w	1	1	key	key	NN
cord-302018-3rlya16w	1	2	:	:	:
cord-302018-3rlya16w	2	1	cord-302018	cord-302018	NNP
cord-302018-3rlya16w	2	2	-	-	HYPH
cord-302018-3rlya16w	2	3	3rlya16w	3rlya16w	CD
cord-302018-3rlya16w	2	4	authors	author	NNS
cord-302018-3rlya16w	2	5	:	:	:
cord-302018-3rlya16w	2	6	Castells	Castells	NNP
cord-302018-3rlya16w	2	7	,	,	,
cord-302018-3rlya16w	2	8	Mariana	Mariana	NNP
cord-302018-3rlya16w	2	9	C.	C.	NNP
cord-302018-3rlya16w	2	10	title	title	NN
cord-302018-3rlya16w	2	11	:	:	:
cord-302018-3rlya16w	3	1	Drug	drug	NN
cord-302018-3rlya16w	3	2	allergy	allergy	NN
cord-302018-3rlya16w	3	3	labeling	labeling	NN
cord-302018-3rlya16w	3	4	and	and	CC
cord-302018-3rlya16w	3	5	delabeling	delabeling	NN
cord-302018-3rlya16w	3	6	in	in	IN
cord-302018-3rlya16w	3	7	the	the	DT
cord-302018-3rlya16w	3	8	coronavirus	coronavirus	NN
cord-302018-3rlya16w	3	9	disease	disease	NN
cord-302018-3rlya16w	3	10	2019	2019	CD
cord-302018-3rlya16w	3	11	era	era	NN
cord-302018-3rlya16w	4	1	:	:	:
cord-302018-3rlya16w	4	2	What	what	WP
cord-302018-3rlya16w	4	3	is	be	VBZ
cord-302018-3rlya16w	4	4	important	important	JJ
cord-302018-3rlya16w	4	5	and	and	CC
cord-302018-3rlya16w	4	6	what	what	WP
cord-302018-3rlya16w	4	7	do	do	VBP
cord-302018-3rlya16w	4	8	we	-PRON-	PRP
cord-302018-3rlya16w	4	9	need	need	VB
cord-302018-3rlya16w	4	10	to	to	TO
cord-302018-3rlya16w	4	11	know	know	VB
cord-302018-3rlya16w	4	12	date	date	NN
cord-302018-3rlya16w	4	13	:	:	:
cord-302018-3rlya16w	5	1	2020	2020	CD
cord-302018-3rlya16w	5	2	-	-	SYM
cord-302018-3rlya16w	5	3	05	05	CD
cord-302018-3rlya16w	5	4	-	-	HYPH
cord-302018-3rlya16w	5	5	22	22	CD
cord-302018-3rlya16w	5	6	journal	journal	NN
cord-302018-3rlya16w	5	7	:	:	:
cord-302018-3rlya16w	6	1	Ann	Ann	NNP
cord-302018-3rlya16w	6	2	Allergy	Allergy	NNP
cord-302018-3rlya16w	6	3	Asthma	Asthma	NNP
cord-302018-3rlya16w	7	1	Immunol	Immunol	NNP
cord-302018-3rlya16w	7	2	DOI	DOI	NNP
cord-302018-3rlya16w	7	3	:	:	:
cord-302018-3rlya16w	7	4	10.1016	10.1016	CD
cord-302018-3rlya16w	7	5	/	/	SYM
cord-302018-3rlya16w	7	6	j.anai.2020.04.012	j.anai.2020.04.012	NNP
cord-302018-3rlya16w	7	7	sha	sha	NNP
cord-302018-3rlya16w	7	8	:	:	:
cord-302018-3rlya16w	7	9	1d0c5ad50aa0d33e2be21020d7363772db54d838	1d0c5ad50aa0d33e2be21020d7363772db54d838	CD
cord-302018-3rlya16w	7	10	doc_id	doc_id	CD
cord-302018-3rlya16w	7	11	:	:	:
cord-302018-3rlya16w	7	12	302018	302018	CD
cord-302018-3rlya16w	7	13	cord_uid	cord_uid	NNS
cord-302018-3rlya16w	7	14	:	:	:
cord-302018-3rlya16w	8	1	3rlya16w	3rlya16w	LS
cord-302018-3rlya16w	8	2	nan	nan	NNP
cord-302018-3rlya16w	8	3	Drug	Drug	NNP
cord-302018-3rlya16w	8	4	allergy	allergy	NN
cord-302018-3rlya16w	8	5	labeling	labeling	NN
cord-302018-3rlya16w	8	6	and	and	CC
cord-302018-3rlya16w	8	7	delabeling	delabeling	NN
cord-302018-3rlya16w	8	8	in	in	IN
cord-302018-3rlya16w	8	9	the	the	DT
cord-302018-3rlya16w	8	10	coronavirus	coronavirus	NN
cord-302018-3rlya16w	8	11	disease	disease	NN
cord-302018-3rlya16w	8	12	2019	2019	CD
cord-302018-3rlya16w	8	13	era	era	NN
cord-302018-3rlya16w	9	1	What	what	WP
cord-302018-3rlya16w	9	2	is	be	VBZ
cord-302018-3rlya16w	9	3	important	important	JJ
cord-302018-3rlya16w	9	4	and	and	CC
cord-302018-3rlya16w	9	5	what	what	WP
cord-302018-3rlya16w	9	6	do	do	VBP
cord-302018-3rlya16w	9	7	we	-PRON-	PRP
cord-302018-3rlya16w	9	8	need	need	VB
cord-302018-3rlya16w	9	9	to	to	TO
cord-302018-3rlya16w	9	10	know	know	VB
cord-302018-3rlya16w	10	1	At	at	IN
cord-302018-3rlya16w	10	2	the	the	DT
cord-302018-3rlya16w	10	3	time	time	NN
cord-302018-3rlya16w	10	4	of	of	IN
cord-302018-3rlya16w	10	5	this	this	DT
cord-302018-3rlya16w	10	6	writing	writing	NN
cord-302018-3rlya16w	10	7	,	,	,
cord-302018-3rlya16w	10	8	April	April	NNP
cord-302018-3rlya16w	10	9	7	7	CD
cord-302018-3rlya16w	10	10	,	,	,
cord-302018-3rlya16w	10	11	2020	2020	CD
cord-302018-3rlya16w	10	12	,	,	,
cord-302018-3rlya16w	10	13	more	more	JJR
cord-302018-3rlya16w	10	14	than	than	IN
cord-302018-3rlya16w	10	15	1.2	1.2	CD
cord-302018-3rlya16w	10	16	million	million	CD
cord-302018-3rlya16w	10	17	people	people	NNS
cord-302018-3rlya16w	10	18	worldwide	worldwide	RB
cord-302018-3rlya16w	10	19	are	be	VBP
cord-302018-3rlya16w	10	20	infected	infect	VBN
cord-302018-3rlya16w	10	21	and	and	CC
cord-302018-3rlya16w	10	22	more	more	JJR
cord-302018-3rlya16w	10	23	than	than	IN
cord-302018-3rlya16w	10	24	68,000	68,000	CD
cord-302018-3rlya16w	10	25	have	have	VBP
cord-302018-3rlya16w	10	26	died	die	VBN
cord-302018-3rlya16w	10	27	because	because	IN
cord-302018-3rlya16w	10	28	of	of	IN
cord-302018-3rlya16w	10	29	coronavirus	coronavirus	NN
cord-302018-3rlya16w	10	30	disease	disease	NN
cord-302018-3rlya16w	10	31	2019	2019	CD
cord-302018-3rlya16w	10	32	(	(	-LRB-
cord-302018-3rlya16w	10	33	COVID-19	COVID-19	NNP
cord-302018-3rlya16w	10	34	)	)	-RRB-
cord-302018-3rlya16w	10	35	induced	induce	VBN
cord-302018-3rlya16w	10	36	by	by	IN
cord-302018-3rlya16w	10	37	the	the	DT
cord-302018-3rlya16w	10	38	novel	novel	JJ
cord-302018-3rlya16w	10	39	severe	severe	JJ
cord-302018-3rlya16w	10	40	acute	acute	JJ
cord-302018-3rlya16w	10	41	respiratory	respiratory	JJ
cord-302018-3rlya16w	10	42	syndrome	syndrome	NN
cord-302018-3rlya16w	10	43	coronavirus	coronavirus	NN
cord-302018-3rlya16w	10	44	2	2	CD
cord-302018-3rlya16w	10	45	infection	infection	NN
cord-302018-3rlya16w	10	46	,	,	,
cord-302018-3rlya16w	10	47	and	and	CC
cord-302018-3rlya16w	10	48	this	this	DT
cord-302018-3rlya16w	10	49	figure	figure	NN
cord-302018-3rlya16w	10	50	will	will	MD
cord-302018-3rlya16w	10	51	surely	surely	RB
cord-302018-3rlya16w	10	52	multiply	multiply	VB
cord-302018-3rlya16w	10	53	in	in	IN
cord-302018-3rlya16w	10	54	the	the	DT
cord-302018-3rlya16w	10	55	next	next	JJ
cord-302018-3rlya16w	10	56	few	few	JJ
cord-302018-3rlya16w	10	57	weeks	week	NNS
cord-302018-3rlya16w	10	58	according	accord	VBG
cord-302018-3rlya16w	10	59	to	to	IN
cord-302018-3rlya16w	10	60	Dr	Dr	NNP
cord-302018-3rlya16w	10	61	Anthony	Anthony	NNP
cord-302018-3rlya16w	10	62	Fauci	Fauci	NNP
cord-302018-3rlya16w	10	63	,	,	,
cord-302018-3rlya16w	10	64	head	head	NN
cord-302018-3rlya16w	10	65	of	of	IN
cord-302018-3rlya16w	10	66	the	the	DT
cord-302018-3rlya16w	10	67	National	National	NNP
cord-302018-3rlya16w	10	68	Institute	Institute	NNP
cord-302018-3rlya16w	10	69	of	of	IN
cord-302018-3rlya16w	10	70	Allergy	Allergy	NNP
cord-302018-3rlya16w	10	71	and	and	CC
cord-302018-3rlya16w	10	72	Infectious	Infectious	NNP
cord-302018-3rlya16w	10	73	Diseases	Diseases	NNPS
cord-302018-3rlya16w	10	74	.	.	.
cord-302018-3rlya16w	11	1	Severe	severe	JJ
cord-302018-3rlya16w	11	2	acute	acute	JJ
cord-302018-3rlya16w	11	3	respiratory	respiratory	JJ
cord-302018-3rlya16w	11	4	syndrome	syndrome	NN
cord-302018-3rlya16w	11	5	coronavirus	coronavirus	NN
cord-302018-3rlya16w	11	6	2	2	CD
cord-302018-3rlya16w	11	7	uses	use	VBZ
cord-302018-3rlya16w	11	8	angiotensin	angiotensin	NN
cord-302018-3rlya16w	11	9	-	-	HYPH
cord-302018-3rlya16w	11	10	converting	convert	VBG
cord-302018-3rlya16w	11	11	enzyme-2	enzyme-2	NNP
cord-302018-3rlya16w	12	1	(	(	-LRB-
cord-302018-3rlya16w	12	2	ACE-2	ACE-2	NNP
cord-302018-3rlya16w	12	3	)	)	-RRB-
cord-302018-3rlya16w	12	4	(	(	-LRB-
cord-302018-3rlya16w	12	5	a	a	DT
cord-302018-3rlya16w	12	6	type	type	NN
cord-302018-3rlya16w	12	7	I	-PRON-	PRP
cord-302018-3rlya16w	12	8	transmembrane	transmembrane	JJ
cord-302018-3rlya16w	12	9	metallocarboxypeptidase	metallocarboxypeptidase	NN
cord-302018-3rlya16w	12	10	)	)	-RRB-
cord-302018-3rlya16w	12	11	as	as	IN
cord-302018-3rlya16w	12	12	its	-PRON-	PRP$
cord-302018-3rlya16w	12	13	preferred	preferred	JJ
cord-302018-3rlya16w	12	14	entry	entry	NN
cord-302018-3rlya16w	12	15	receptor	receptor	NN
cord-302018-3rlya16w	12	16	.	.	.
cord-302018-3rlya16w	13	1	The	the	DT
cord-302018-3rlya16w	13	2	expression	expression	NN
cord-302018-3rlya16w	13	3	of	of	IN
cord-302018-3rlya16w	13	4	ACE-2	ACE-2	NNP
cord-302018-3rlya16w	13	5	is	be	VBZ
cord-302018-3rlya16w	13	6	high	high	JJ
cord-302018-3rlya16w	13	7	in	in	IN
cord-302018-3rlya16w	13	8	alveolar	alveolar	NN
cord-302018-3rlya16w	13	9	and	and	CC
cord-302018-3rlya16w	13	10	epithelial	epithelial	JJ
cord-302018-3rlya16w	13	11	tissues	tissue	NNS
cord-302018-3rlya16w	13	12	in	in	IN
cord-302018-3rlya16w	13	13	the	the	DT
cord-302018-3rlya16w	13	14	lungs	lung	NNS
cord-302018-3rlya16w	13	15	and	and	CC
cord-302018-3rlya16w	13	16	the	the	DT
cord-302018-3rlya16w	13	17	gastrointestinal	gastrointestinal	JJ
cord-302018-3rlya16w	13	18	tract	tract	NN
cord-302018-3rlya16w	13	19	.	.	.
cord-302018-3rlya16w	14	1	Drugs	drug	NNS
cord-302018-3rlya16w	14	2	which	which	WDT
cord-302018-3rlya16w	14	3	affect	affect	VBP
cord-302018-3rlya16w	14	4	the	the	DT
cord-302018-3rlya16w	14	5	expression	expression	NN
cord-302018-3rlya16w	14	6	of	of	IN
cord-302018-3rlya16w	14	7	ACE-2	ACE-2	NNP
cord-302018-3rlya16w	14	8	(	(	-LRB-
cord-302018-3rlya16w	14	9	such	such	JJ
cord-302018-3rlya16w	14	10	as	as	IN
cord-302018-3rlya16w	14	11	ACE	ace	NN
cord-302018-3rlya16w	14	12	inhibitors	inhibitor	NNS
cord-302018-3rlya16w	14	13	and	and	CC
cord-302018-3rlya16w	14	14	angiotensin	angiotensin	NN
cord-302018-3rlya16w	14	15	receptor	receptor	NN
cord-302018-3rlya16w	14	16	blockers	blocker	NNS
cord-302018-3rlya16w	14	17	)	)	-RRB-
cord-302018-3rlya16w	14	18	are	be	VBP
cord-302018-3rlya16w	14	19	being	be	VBG
cord-302018-3rlya16w	14	20	investigated	investigate	VBN
cord-302018-3rlya16w	14	21	as	as	IN
cord-302018-3rlya16w	14	22	possible	possible	JJ
cord-302018-3rlya16w	14	23	risk	risk	NN
cord-302018-3rlya16w	14	24	factors	factor	NNS
cord-302018-3rlya16w	14	25	for	for	IN
cord-302018-3rlya16w	14	26	the	the	DT
cord-302018-3rlya16w	14	27	severity	severity	NN
cord-302018-3rlya16w	14	28	of	of	IN
cord-302018-3rlya16w	14	29	coronavirus	coronavirus	NN
cord-302018-3rlya16w	14	30	disease	disease	NN
cord-302018-3rlya16w	14	31	2019	2019	CD
cord-302018-3rlya16w	14	32	.	.	.
cord-302018-3rlya16w	15	1	1	1	LS
cord-302018-3rlya16w	16	1	Nonsteroidal	nonsteroidal	JJ
cord-302018-3rlya16w	16	2	antiinflammatory	antiinflammatory	JJ
cord-302018-3rlya16w	16	3	drugs	drug	NNS
cord-302018-3rlya16w	16	4	are	be	VBP
cord-302018-3rlya16w	16	5	being	be	VBG
cord-302018-3rlya16w	16	6	similarly	similarly	RB
cord-302018-3rlya16w	16	7	investigated	investigate	VBN
cord-302018-3rlya16w	16	8	.	.	.
cord-302018-3rlya16w	17	1	2	2	LS
cord-302018-3rlya16w	17	2	Clinical	clinical	JJ
cord-302018-3rlya16w	17	3	trials	trial	NNS
cord-302018-3rlya16w	17	4	with	with	IN
cord-302018-3rlya16w	17	5	azithromycin	azithromycin	NNP
cord-302018-3rlya16w	17	6	and	and	CC
cord-302018-3rlya16w	17	7	hydroxychloroquine	hydroxychloroquine	NNP
cord-302018-3rlya16w	17	8	,	,	,
cord-302018-3rlya16w	17	9	3	3	CD
cord-302018-3rlya16w	17	10	antiretroviral	antiretroviral	JJ
cord-302018-3rlya16w	17	11	drugs	drug	NNS
cord-302018-3rlya16w	17	12	,	,	,
cord-302018-3rlya16w	17	13	4	4	CD
cord-302018-3rlya16w	17	14	and	and	CC
cord-302018-3rlya16w	17	15	antieinterleukin-6	antieinterleukin-6	NNP
cord-302018-3rlya16w	17	16	5	5	CD
cord-302018-3rlya16w	17	17	are	be	VBP
cord-302018-3rlya16w	17	18	ongoing	ongoing	JJ
cord-302018-3rlya16w	17	19	in	in	IN
cord-302018-3rlya16w	17	20	an	an	DT
cord-302018-3rlya16w	17	21	attempt	attempt	NN
cord-302018-3rlya16w	17	22	to	to	TO
cord-302018-3rlya16w	17	23	improve	improve	VB
cord-302018-3rlya16w	17	24	disease	disease	NN
cord-302018-3rlya16w	17	25	outcomes	outcome	NNS
cord-302018-3rlya16w	17	26	before	before	IN
cord-302018-3rlya16w	17	27	a	a	DT
cord-302018-3rlya16w	17	28	vaccine	vaccine	NN
cord-302018-3rlya16w	17	29	can	can	MD
cord-302018-3rlya16w	17	30	be	be	VB
cord-302018-3rlya16w	17	31	available	available	JJ
cord-302018-3rlya16w	17	32	.	.	.
cord-302018-3rlya16w	18	1	This	this	DT
cord-302018-3rlya16w	18	2	provides	provide	VBZ
cord-302018-3rlya16w	18	3	a	a	DT
cord-302018-3rlya16w	18	4	glimpse	glimpse	NN
cord-302018-3rlya16w	18	5	of	of	IN
cord-302018-3rlya16w	18	6	the	the	DT
cord-302018-3rlya16w	18	7	complexities	complexity	NNS
cord-302018-3rlya16w	18	8	of	of	IN
cord-302018-3rlya16w	18	9	this	this	DT
cord-302018-3rlya16w	18	10	disease	disease	NN
cord-302018-3rlya16w	18	11	and	and	CC
cord-302018-3rlya16w	18	12	reveals	reveal	VBZ
cord-302018-3rlya16w	18	13	the	the	DT
cord-302018-3rlya16w	18	14	importance	importance	NN
cord-302018-3rlya16w	18	15	of	of	IN
cord-302018-3rlya16w	18	16	identifying	identify	VBG
cord-302018-3rlya16w	18	17	candidate	candidate	NN
cord-302018-3rlya16w	18	18	drugs	drug	NNS
cord-302018-3rlya16w	18	19	for	for	IN
cord-302018-3rlya16w	18	20	clinical	clinical	JJ
cord-302018-3rlya16w	18	21	trials	trial	NNS
cord-302018-3rlya16w	18	22	that	that	WDT
cord-302018-3rlya16w	18	23	may	may	MD
cord-302018-3rlya16w	18	24	save	save	VB
cord-302018-3rlya16w	18	25	lives	life	NNS
cord-302018-3rlya16w	18	26	.	.	.
cord-302018-3rlya16w	19	1	It	-PRON-	PRP
cord-302018-3rlya16w	19	2	follows	follow	VBZ
cord-302018-3rlya16w	19	3	in	in	IN
cord-302018-3rlya16w	19	4	importance	importance	NN
cord-302018-3rlya16w	19	5	to	to	TO
cord-302018-3rlya16w	19	6	identify	identify	VB
cord-302018-3rlya16w	19	7	patients	patient	NNS
cord-302018-3rlya16w	19	8	with	with	IN
cord-302018-3rlya16w	19	9	allergy	allergy	NN
cord-302018-3rlya16w	19	10	who	who	WP
cord-302018-3rlya16w	19	11	are	be	VBP
cord-302018-3rlya16w	19	12	at	at	IN
cord-302018-3rlya16w	19	13	risk	risk	NN
cord-302018-3rlya16w	19	14	,	,	,
cord-302018-3rlya16w	19	15	if	if	IN
cord-302018-3rlya16w	19	16	treated	treat	VBN
cord-302018-3rlya16w	19	17	,	,	,
cord-302018-3rlya16w	19	18	and	and	CC
cord-302018-3rlya16w	19	19	who	who	WP
cord-302018-3rlya16w	19	20	may	may	MD
cord-302018-3rlya16w	19	21	need	need	VB
cord-302018-3rlya16w	19	22	desensitization	desensitization	NN
cord-302018-3rlya16w	19	23	.	.	.
cord-302018-3rlya16w	20	1	Understanding	understand	VBG
cord-302018-3rlya16w	20	2	the	the	DT
cord-302018-3rlya16w	20	3	mechanisms	mechanism	NNS
cord-302018-3rlya16w	20	4	of	of	IN
cord-302018-3rlya16w	20	5	drug	drug	NN
cord-302018-3rlya16w	20	6	allergy	allergy	NN
cord-302018-3rlya16w	20	7	6	6	CD
cord-302018-3rlya16w	20	8	is	be	VBZ
cord-302018-3rlya16w	20	9	key	key	JJ
cord-302018-3rlya16w	20	10	,	,	,
cord-302018-3rlya16w	20	11	given	give	VBN
cord-302018-3rlya16w	20	12	that	that	IN
cord-302018-3rlya16w	20	13	the	the	DT
cord-302018-3rlya16w	20	14	classification	classification	NN
cord-302018-3rlya16w	20	15	of	of	IN
cord-302018-3rlya16w	20	16	drug	drug	NN
cord-302018-3rlya16w	20	17	hypersensitivity	hypersensitivity	NN
cord-302018-3rlya16w	20	18	continues	continue	VBZ
cord-302018-3rlya16w	20	19	to	to	TO
cord-302018-3rlya16w	20	20	expand	expand	VB
cord-302018-3rlya16w	20	21	.	.	.
cord-302018-3rlya16w	21	1	7	7	CD
cord-302018-3rlya16w	21	2	Cytokine	cytokine	NN
cord-302018-3rlya16w	21	3	stormelike	stormelike	JJ
cord-302018-3rlya16w	21	4	reactions	reaction	NNS
cord-302018-3rlya16w	21	5	with	with	IN
cord-302018-3rlya16w	21	6	elevated	elevated	JJ
cord-302018-3rlya16w	21	7	interleukin-6	interleukin-6	NNP
cord-302018-3rlya16w	21	8	can	can	MD
cord-302018-3rlya16w	21	9	be	be	VB
cord-302018-3rlya16w	21	10	seen	see	VBN
cord-302018-3rlya16w	21	11	in	in	IN
cord-302018-3rlya16w	21	12	patients	patient	NNS
cord-302018-3rlya16w	21	13	treated	treat	VBN
cord-302018-3rlya16w	21	14	with	with	IN
cord-302018-3rlya16w	21	15	chemotherapy	chemotherapy	NN
cord-302018-3rlya16w	21	16	and	and	CC
cord-302018-3rlya16w	21	17	monoclonal	monoclonal	JJ
cord-302018-3rlya16w	21	18	antibodies	antibody	NNS
cord-302018-3rlya16w	21	19	8	8	CD
cord-302018-3rlya16w	21	20	and	and	CC
cord-302018-3rlya16w	21	21	are	be	VBP
cord-302018-3rlya16w	21	22	now	now	RB
cord-302018-3rlya16w	21	23	part	part	NN
cord-302018-3rlya16w	21	24	of	of	IN
cord-302018-3rlya16w	21	25	a	a	DT
cord-302018-3rlya16w	21	26	broader	broad	JJR
cord-302018-3rlya16w	21	27	definition	definition	NN
cord-302018-3rlya16w	21	28	of	of	IN
cord-302018-3rlya16w	21	29	anaphylaxis	anaphylaxis	NN
cord-302018-3rlya16w	21	30	,	,	,
cord-302018-3rlya16w	21	31	allowing	allow	VBG
cord-302018-3rlya16w	21	32	for	for	IN
cord-302018-3rlya16w	21	33	better	well	JJR
cord-302018-3rlya16w	21	34	management	management	NN
cord-302018-3rlya16w	21	35	and	and	CC
cord-302018-3rlya16w	21	36	treatment	treatment	NN
cord-302018-3rlya16w	21	37	options	option	NNS
cord-302018-3rlya16w	21	38	.	.	.
cord-302018-3rlya16w	22	1	The	the	DT
cord-302018-3rlya16w	22	2	timing	timing	NN
cord-302018-3rlya16w	22	3	of	of	IN
cord-302018-3rlya16w	22	4	this	this	DT
cord-302018-3rlya16w	22	5	issue	issue	NN
cord-302018-3rlya16w	22	6	of	of	IN
cord-302018-3rlya16w	22	7	the	the	DT
cord-302018-3rlya16w	22	8	Annals	Annals	NNP
cord-302018-3rlya16w	22	9	is	be	VBZ
cord-302018-3rlya16w	22	10	highly	highly	RB
cord-302018-3rlya16w	22	11	relevant	relevant	JJ
cord-302018-3rlya16w	22	12	given	give	VBN
cord-302018-3rlya16w	22	13	that	that	IN
cord-302018-3rlya16w	22	14	it	-PRON-	PRP
cord-302018-3rlya16w	22	15	is	be	VBZ
cord-302018-3rlya16w	22	16	dedicated	dedicated	JJ
cord-302018-3rlya16w	22	17	to	to	IN
cord-302018-3rlya16w	22	18	broadening	broaden	VBG
cord-302018-3rlya16w	22	19	our	-PRON-	PRP$
cord-302018-3rlya16w	22	20	understanding	understanding	NN
cord-302018-3rlya16w	22	21	of	of	IN
cord-302018-3rlya16w	22	22	the	the	DT
cord-302018-3rlya16w	22	23	scope	scope	NN
cord-302018-3rlya16w	22	24	of	of	IN
cord-302018-3rlya16w	22	25	drug	drug	NN
cord-302018-3rlya16w	22	26	allergy	allergy	NN
cord-302018-3rlya16w	22	27	in	in	IN
cord-302018-3rlya16w	22	28	the	the	DT
cord-302018-3rlya16w	22	29	general	general	JJ
cord-302018-3rlya16w	22	30	population	population	NN
cord-302018-3rlya16w	22	31	.	.	.
cord-302018-3rlya16w	23	1	Various	various	JJ
cord-302018-3rlya16w	23	2	tools	tool	NNS
cord-302018-3rlya16w	23	3	can	can	MD
cord-302018-3rlya16w	23	4	be	be	VB
cord-302018-3rlya16w	23	5	used	use	VBN
cord-302018-3rlya16w	23	6	in	in	IN
cord-302018-3rlya16w	23	7	personalized	personalized	JJ
cord-302018-3rlya16w	23	8	medicine	medicine	NN
cord-302018-3rlya16w	23	9	to	to	TO
cord-302018-3rlya16w	23	10	confirm	confirm	VB
cord-302018-3rlya16w	23	11	or	or	CC
cord-302018-3rlya16w	23	12	refute	refute	VB
cord-302018-3rlya16w	23	13	specific	specific	JJ
cord-302018-3rlya16w	23	14	drug	drug	NN
cord-302018-3rlya16w	23	15	allergy	allergy	NN
cord-302018-3rlya16w	23	16	status	status	NN
cord-302018-3rlya16w	23	17	through	through	IN
cord-302018-3rlya16w	23	18	delabeling	delabeling	NN
cord-302018-3rlya16w	23	19	.	.	.
cord-302018-3rlya16w	24	1	These	these	DT
cord-302018-3rlya16w	24	2	standardized	standardize	VBN
cord-302018-3rlya16w	24	3	diagnostic	diagnostic	JJ
cord-302018-3rlya16w	24	4	interventions	intervention	NNS
cord-302018-3rlya16w	24	5	can	can	MD
cord-302018-3rlya16w	24	6	allow	allow	VB
cord-302018-3rlya16w	24	7	both	both	DT
cord-302018-3rlya16w	24	8	children	child	NNS
cord-302018-3rlya16w	24	9	and	and	CC
cord-302018-3rlya16w	24	10	adults	adult	NNS
cord-302018-3rlya16w	24	11	to	to	TO
cord-302018-3rlya16w	24	12	safely	safely	RB
cord-302018-3rlya16w	24	13	take	take	VB
cord-302018-3rlya16w	24	14	the	the	DT
cord-302018-3rlya16w	24	15	drug	drug	NN
cord-302018-3rlya16w	24	16	for	for	IN
cord-302018-3rlya16w	24	17	which	which	WDT
cord-302018-3rlya16w	24	18	they	-PRON-	PRP
cord-302018-3rlya16w	24	19	had	have	VBD
cord-302018-3rlya16w	24	20	been	be	VBN
cord-302018-3rlya16w	24	21	previously	previously	RB
cord-302018-3rlya16w	24	22	labeled	label	VBN
cord-302018-3rlya16w	24	23	as	as	IN
cord-302018-3rlya16w	24	24	allergic	allergic	JJ
cord-302018-3rlya16w	24	25	,	,	,
cord-302018-3rlya16w	24	26	thereby	thereby	RB
cord-302018-3rlya16w	24	27	resulting	result	VBG
cord-302018-3rlya16w	24	28	in	in	IN
cord-302018-3rlya16w	24	29	the	the	DT
cord-302018-3rlya16w	24	30	removal	removal	NN
cord-302018-3rlya16w	24	31	of	of	IN
cord-302018-3rlya16w	24	32	this	this	DT
cord-302018-3rlya16w	24	33	label	label	NN
cord-302018-3rlya16w	24	34	.	.	.
cord-302018-3rlya16w	25	1	The	the	DT
cord-302018-3rlya16w	25	2	topics	topic	NNS
cord-302018-3rlya16w	25	3	covered	cover	VBN
cord-302018-3rlya16w	25	4	in	in	IN
cord-302018-3rlya16w	25	5	this	this	DT
cord-302018-3rlya16w	25	6	issue	issue	NN
cord-302018-3rlya16w	25	7	provide	provide	VBP
cord-302018-3rlya16w	25	8	the	the	DT
cord-302018-3rlya16w	25	9	necessary	necessary	JJ
cord-302018-3rlya16w	25	10	and	and	CC
cord-302018-3rlya16w	25	11	updated	update	VBN
cord-302018-3rlya16w	25	12	knowledge	knowledge	NN
cord-302018-3rlya16w	25	13	for	for	IN
cord-302018-3rlya16w	25	14	all	all	DT
cord-302018-3rlya16w	25	15	allergists	allergist	NNS
cord-302018-3rlya16w	25	16	involved	involve	VBN
cord-302018-3rlya16w	25	17	in	in	IN
cord-302018-3rlya16w	25	18	labeling	label	VBG
cord-302018-3rlya16w	25	19	and	and	CC
cord-302018-3rlya16w	25	20	delabeling	delabeling	NN
cord-302018-3rlya16w	25	21	procedures	procedure	NNS
cord-302018-3rlya16w	25	22	,	,	,
cord-302018-3rlya16w	25	23	aiming	aim	VBG
cord-302018-3rlya16w	25	24	to	to	TO
cord-302018-3rlya16w	25	25	broaden	broaden	VB
cord-302018-3rlya16w	25	26	drug	drug	NN
cord-302018-3rlya16w	25	27	choices	choice	NNS
cord-302018-3rlya16w	25	28	and	and	CC
cord-302018-3rlya16w	25	29	treatment	treatment	NN
cord-302018-3rlya16w	25	30	options	option	NNS
cord-302018-3rlya16w	25	31	for	for	IN
cord-302018-3rlya16w	25	32	patients	patient	NNS
cord-302018-3rlya16w	25	33	in	in	IN
cord-302018-3rlya16w	25	34	this	this	DT
cord-302018-3rlya16w	25	35	unknown	unknown	JJ
cord-302018-3rlya16w	25	36	world	world	NN
cord-302018-3rlya16w	25	37	of	of	IN
cord-302018-3rlya16w	25	38	COVID-19	covid-19	JJ
cord-302018-3rlya16w	25	39	pandemic	pandemic	NN
cord-302018-3rlya16w	25	40	and	and	CC
cord-302018-3rlya16w	25	41	other	other	JJ
cord-302018-3rlya16w	25	42	disease	disease	NN
cord-302018-3rlya16w	25	43	states	state	NNS
cord-302018-3rlya16w	25	44	.	.	.
cord-302018-3rlya16w	26	1	Our	-PRON-	PRP$
cord-302018-3rlya16w	26	2	first	first	JJ
cord-302018-3rlya16w	26	3	question	question	NN
cord-302018-3rlya16w	26	4	is	be	VBZ
cord-302018-3rlya16w	26	5	:	:	:
cord-302018-3rlya16w	26	6	who	who	WP
cord-302018-3rlya16w	26	7	is	be	VBZ
cord-302018-3rlya16w	26	8	labeled	label	VBN
cord-302018-3rlya16w	26	9	as	as	IN
cord-302018-3rlya16w	26	10	drug	drug	NN
cord-302018-3rlya16w	26	11	allergic	allergic	JJ
cord-302018-3rlya16w	26	12	in	in	IN
cord-302018-3rlya16w	26	13	the	the	DT
cord-302018-3rlya16w	26	14	general	general	JJ
cord-302018-3rlya16w	26	15	population	population	NN
cord-302018-3rlya16w	26	16	and	and	CC
cord-302018-3rlya16w	26	17	what	what	WP
cord-302018-3rlya16w	26	18	can	can	MD
cord-302018-3rlya16w	26	19	be	be	VB
cord-302018-3rlya16w	26	20	done	do	VBN
cord-302018-3rlya16w	26	21	to	to	TO
cord-302018-3rlya16w	26	22	uncover	uncover	VB
cord-302018-3rlya16w	26	23	true	true	JJ
cord-302018-3rlya16w	26	24	drug	drug	NN
cord-302018-3rlya16w	26	25	allergy	allergy	NN
cord-302018-3rlya16w	26	26	?	?	.
cord-302018-3rlya16w	27	1	A	a	DT
cord-302018-3rlya16w	27	2	review	review	NN
cord-302018-3rlya16w	27	3	by	by	IN
cord-302018-3rlya16w	27	4	Macy	Macy	NNP
cord-302018-3rlya16w	27	5	9	9	CD
cord-302018-3rlya16w	27	6	provides	provide	VBZ
cord-302018-3rlya16w	27	7	data	datum	NNS
cord-302018-3rlya16w	27	8	on	on	IN
cord-302018-3rlya16w	27	9	a	a	DT
cord-302018-3rlya16w	27	10	large	large	JJ
cord-302018-3rlya16w	27	11	cohort	cohort	NN
cord-302018-3rlya16w	27	12	of	of	IN
cord-302018-3rlya16w	27	13	more	more	JJR
cord-302018-3rlya16w	27	14	than	than	IN
cord-302018-3rlya16w	27	15	2	2	CD
cord-302018-3rlya16w	27	16	million	million	CD
cord-302018-3rlya16w	27	17	members	member	NNS
cord-302018-3rlya16w	27	18	of	of	IN
cord-302018-3rlya16w	27	19	Kaiser	Kaiser	NNP
cord-302018-3rlya16w	27	20	Health	Health	NNP
cord-302018-3rlya16w	27	21	Care	Care	NNP
cord-302018-3rlya16w	27	22	,	,	,
cord-302018-3rlya16w	27	23	with	with	IN
cord-302018-3rlya16w	27	24	20	20	CD
cord-302018-3rlya16w	27	25	%	%	NN
cord-302018-3rlya16w	27	26	reported	report	VBN
cord-302018-3rlya16w	27	27	to	to	TO
cord-302018-3rlya16w	27	28	have	have	VB
cord-302018-3rlya16w	27	29	a	a	DT
cord-302018-3rlya16w	27	30	drug	drug	NN
cord-302018-3rlya16w	27	31	allergy	allergy	NN
cord-302018-3rlya16w	27	32	and	and	CC
cord-302018-3rlya16w	27	33	more	more	JJR
cord-302018-3rlya16w	27	34	than	than	IN
cord-302018-3rlya16w	27	35	13	13	CD
cord-302018-3rlya16w	27	36	%	%	NN
cord-302018-3rlya16w	27	37	having	have	VBG
cord-302018-3rlya16w	27	38	antibiotic	antibiotic	JJ
cord-302018-3rlya16w	27	39	allergy	allergy	NN
cord-302018-3rlya16w	27	40	.	.	.
cord-302018-3rlya16w	28	1	In	in	IN
cord-302018-3rlya16w	28	2	this	this	DT
cord-302018-3rlya16w	28	3	drug	drug	NN
cord-302018-3rlya16w	28	4	allergy	allergy	NN
cord-302018-3rlya16w	28	5	cohort	cohort	NN
cord-302018-3rlya16w	28	6	,	,	,
cord-302018-3rlya16w	28	7	twice	twice	RB
cord-302018-3rlya16w	28	8	as	as	RB
cord-302018-3rlya16w	28	9	many	many	JJ
cord-302018-3rlya16w	28	10	patients	patient	NNS
cord-302018-3rlya16w	28	11	are	be	VBP
cord-302018-3rlya16w	28	12	females	female	NNS
cord-302018-3rlya16w	28	13	.	.	.
cord-302018-3rlya16w	29	1	Age	age	NN
cord-302018-3rlya16w	29	2	of	of	IN
cord-302018-3rlya16w	29	3	more	more	JJR
cord-302018-3rlya16w	29	4	than	than	IN
cord-302018-3rlya16w	29	5	50	50	CD
cord-302018-3rlya16w	29	6	years	year	NNS
cord-302018-3rlya16w	29	7	and	and	CC
cord-302018-3rlya16w	29	8	increased	increase	VBN
cord-302018-3rlya16w	29	9	body	body	NN
cord-302018-3rlya16w	29	10	mass	mass	NN
cord-302018-3rlya16w	29	11	index	index	NN
cord-302018-3rlya16w	29	12	were	be	VBD
cord-302018-3rlya16w	29	13	found	find	VBN
cord-302018-3rlya16w	29	14	to	to	TO
cord-302018-3rlya16w	29	15	be	be	VB
cord-302018-3rlya16w	29	16	associated	associate	VBN
cord-302018-3rlya16w	29	17	with	with	IN
cord-302018-3rlya16w	29	18	drug	drug	NN
cord-302018-3rlya16w	29	19	allergy	allergy	NN
cord-302018-3rlya16w	29	20	.	.	.
cord-302018-3rlya16w	30	1	The	the	DT
cord-302018-3rlya16w	30	2	review	review	NN
cord-302018-3rlya16w	30	3	also	also	RB
cord-302018-3rlya16w	30	4	discusses	discuss	VBZ
cord-302018-3rlya16w	30	5	whether	whether	IN
cord-302018-3rlya16w	30	6	drug	drug	NN
cord-302018-3rlya16w	30	7	allergy	allergy	NN
cord-302018-3rlya16w	30	8	and	and	CC
cord-302018-3rlya16w	30	9	hypersensitivity	hypersensitivity	NN
cord-302018-3rlya16w	30	10	are	be	VBP
cord-302018-3rlya16w	30	11	due	due	JJ
cord-302018-3rlya16w	30	12	to	to	IN
cord-302018-3rlya16w	30	13	increased	increase	VBN
cord-302018-3rlya16w	30	14	use	use	NN
cord-302018-3rlya16w	30	15	,	,	,
cord-302018-3rlya16w	30	16	given	give	VBN
cord-302018-3rlya16w	30	17	that	that	IN
cord-302018-3rlya16w	30	18	countries	country	NNS
cord-302018-3rlya16w	30	19	with	with	IN
cord-302018-3rlya16w	30	20	lower	low	JJR
cord-302018-3rlya16w	30	21	rates	rate	NNS
cord-302018-3rlya16w	30	22	of	of	IN
cord-302018-3rlya16w	30	23	antibiotic	antibiotic	JJ
cord-302018-3rlya16w	30	24	use	use	NN
cord-302018-3rlya16w	30	25	have	have	VBP
cord-302018-3rlya16w	30	26	a	a	DT
cord-302018-3rlya16w	30	27	lower	low	JJR
cord-302018-3rlya16w	30	28	prevalence	prevalence	NN
cord-302018-3rlya16w	30	29	of	of	IN
cord-302018-3rlya16w	30	30	antibiotic	antibiotic	JJ
cord-302018-3rlya16w	30	31	allergy	allergy	NN
cord-302018-3rlya16w	30	32	.	.	.
cord-302018-3rlya16w	31	1	Inappropriate	inappropriate	JJ
cord-302018-3rlya16w	31	2	use	use	NN
cord-302018-3rlya16w	31	3	of	of	IN
cord-302018-3rlya16w	31	4	antibiotics	antibiotic	NNS
cord-302018-3rlya16w	31	5	is	be	VBZ
cord-302018-3rlya16w	31	6	still	still	RB
cord-302018-3rlya16w	31	7	high	high	JJ
cord-302018-3rlya16w	31	8	in	in	IN
cord-302018-3rlya16w	31	9	the	the	DT
cord-302018-3rlya16w	31	10	setting	setting	NN
cord-302018-3rlya16w	31	11	of	of	IN
cord-302018-3rlya16w	31	12	dental	dental	JJ
cord-302018-3rlya16w	31	13	procedures	procedure	NNS
cord-302018-3rlya16w	31	14	.	.	.
cord-302018-3rlya16w	32	1	Target	target	NN
cord-302018-3rlya16w	32	2	populations	population	NNS
cord-302018-3rlya16w	32	3	for	for	IN
cord-302018-3rlya16w	32	4	receiving	receive	VBG
cord-302018-3rlya16w	32	5	a	a	DT
cord-302018-3rlya16w	32	6	drug	drug	NN
cord-302018-3rlya16w	32	7	allergy	allergy	NN
cord-302018-3rlya16w	32	8	label	label	NN
cord-302018-3rlya16w	32	9	include	include	VBP
cord-302018-3rlya16w	32	10	the	the	DT
cord-302018-3rlya16w	32	11	following	follow	VBG
cord-302018-3rlya16w	32	12	:	:	:
cord-302018-3rlya16w	32	13	(	(	-LRB-
cord-302018-3rlya16w	32	14	1	1	LS
cord-302018-3rlya16w	32	15	)	)	-RRB-
cord-302018-3rlya16w	32	16	children	child	NNS
cord-302018-3rlya16w	32	17	with	with	IN
cord-302018-3rlya16w	32	18	approximately	approximately	RB
cord-302018-3rlya16w	32	19	70,000	70,000	CD
cord-302018-3rlya16w	32	20	visits	visit	NNS
cord-302018-3rlya16w	32	21	to	to	IN
cord-302018-3rlya16w	32	22	the	the	DT
cord-302018-3rlya16w	32	23	emergency	emergency	NN
cord-302018-3rlya16w	32	24	department	department	NN
cord-302018-3rlya16w	32	25	reported	report	VBD
cord-302018-3rlya16w	32	26	annually	annually	RB
cord-302018-3rlya16w	32	27	for	for	IN
cord-302018-3rlya16w	32	28	adverse	adverse	JJ
cord-302018-3rlya16w	32	29	drug	drug	NN
cord-302018-3rlya16w	32	30	events	event	NNS
cord-302018-3rlya16w	32	31	with	with	IN
cord-302018-3rlya16w	32	32	penicillins	penicillin	NNS
cord-302018-3rlya16w	32	33	,	,	,
cord-302018-3rlya16w	32	34	cephalosporins	cephalosporin	NNS
cord-302018-3rlya16w	32	35	,	,	,
cord-302018-3rlya16w	32	36	and	and	CC
cord-302018-3rlya16w	32	37	sulfamethoxazole	sulfamethoxazole	NN
cord-302018-3rlya16w	32	38	-	-	HYPH
cord-302018-3rlya16w	32	39	trimethoprim	trimethoprim	NNP
cord-302018-3rlya16w	32	40	as	as	IN
cord-302018-3rlya16w	32	41	the	the	DT
cord-302018-3rlya16w	32	42	most	most	RBS
cord-302018-3rlya16w	32	43	frequent	frequent	JJ
cord-302018-3rlya16w	32	44	medications	medication	NNS
cord-302018-3rlya16w	32	45	;	;	:
cord-302018-3rlya16w	32	46	and	and	CC
cord-302018-3rlya16w	32	47	(	(	-LRB-
cord-302018-3rlya16w	32	48	2	2	LS
cord-302018-3rlya16w	32	49	)	)	-RRB-
cord-302018-3rlya16w	32	50	hospitalized	hospitalize	VBN
cord-302018-3rlya16w	32	51	patients	patient	NNS
cord-302018-3rlya16w	32	52	with	with	IN
cord-302018-3rlya16w	32	53	cancer	cancer	NN
cord-302018-3rlya16w	32	54	,	,	,
cord-302018-3rlya16w	32	55	of	of	IN
cord-302018-3rlya16w	32	56	whom	whom	WP
cord-302018-3rlya16w	32	57	23	23	CD
cord-302018-3rlya16w	32	58	%	%	NN
cord-302018-3rlya16w	32	59	have	have	VBP
cord-302018-3rlya16w	32	60	a	a	DT
cord-302018-3rlya16w	32	61	label	label	NN
cord-302018-3rlya16w	32	62	of	of	IN
cord-302018-3rlya16w	32	63	antibiotic	antibiotic	JJ
cord-302018-3rlya16w	32	64	allergy	allergy	NN
cord-302018-3rlya16w	32	65	.	.	.
cord-302018-3rlya16w	33	1	What	what	WP
cord-302018-3rlya16w	33	2	are	be	VBP
cord-302018-3rlya16w	33	3	the	the	DT
cord-302018-3rlya16w	33	4	tools	tool	NNS
cord-302018-3rlya16w	33	5	for	for	IN
cord-302018-3rlya16w	33	6	the	the	DT
cord-302018-3rlya16w	33	7	labeling	labeling	NN
cord-302018-3rlya16w	33	8	or	or	CC
cord-302018-3rlya16w	33	9	delabeling	delabeling	NN
cord-302018-3rlya16w	33	10	of	of	IN
cord-302018-3rlya16w	33	11	a	a	DT
cord-302018-3rlya16w	33	12	drug	drug	NN
cord-302018-3rlya16w	33	13	allergy	allergy	NN
cord-302018-3rlya16w	33	14	?	?	.
cord-302018-3rlya16w	34	1	For	for	IN
cord-302018-3rlya16w	34	2	individuals	individual	NNS
cord-302018-3rlya16w	34	3	with	with	IN
cord-302018-3rlya16w	34	4	penicillin	penicillin	NN
cord-302018-3rlya16w	34	5	-	-	HYPH
cord-302018-3rlya16w	34	6	associated	associate	VBN
cord-302018-3rlya16w	34	7	anaphylaxis	anaphylaxis	NN
cord-302018-3rlya16w	34	8	,	,	,
cord-302018-3rlya16w	34	9	penicillin	penicillin	NN
cord-302018-3rlya16w	34	10	skin	skin	NN
cord-302018-3rlya16w	34	11	testing	testing	NN
cord-302018-3rlya16w	34	12	with	with	IN
cord-302018-3rlya16w	34	13	penicilloyl	penicilloyl	JJ
cord-302018-3rlya16w	34	14	-	-	HYPH
cord-302018-3rlya16w	34	15	polylysine	polylysine	NNP
cord-302018-3rlya16w	34	16	before	before	IN
cord-302018-3rlya16w	34	17	oral	oral	JJ
cord-302018-3rlya16w	34	18	amoxicillin	amoxicillin	NNP
cord-302018-3rlya16w	34	19	250	250	CD
cord-302018-3rlya16w	34	20	mg	mg	NNP
cord-302018-3rlya16w	34	21	oral	oral	JJ
cord-302018-3rlya16w	34	22	challenge	challenge	NN
cord-302018-3rlya16w	34	23	(	(	-LRB-
cord-302018-3rlya16w	34	24	if	if	IN
cord-302018-3rlya16w	34	25	skin	skin	NN
cord-302018-3rlya16w	34	26	test	test	NN
cord-302018-3rlya16w	34	27	negative	negative	JJ
cord-302018-3rlya16w	34	28	)	)	-RRB-
cord-302018-3rlya16w	34	29	is	be	VBZ
cord-302018-3rlya16w	34	30	the	the	DT
cord-302018-3rlya16w	34	31	avenue	avenue	NN
cord-302018-3rlya16w	34	32	proposed	propose	VBN
cord-302018-3rlya16w	34	33	by	by	IN
cord-302018-3rlya16w	34	34	the	the	DT
cord-302018-3rlya16w	34	35	author	author	NN
cord-302018-3rlya16w	34	36	;	;	:
cord-302018-3rlya16w	34	37	however	however	RB
cord-302018-3rlya16w	34	38	,	,	,
cord-302018-3rlya16w	34	39	with	with	IN
cord-302018-3rlya16w	34	40	the	the	DT
cord-302018-3rlya16w	34	41	lack	lack	NN
cord-302018-3rlya16w	34	42	of	of	IN
cord-302018-3rlya16w	34	43	minor	minor	JJ
cord-302018-3rlya16w	34	44	determinants	determinant	NNS
cord-302018-3rlya16w	34	45	,	,	,
cord-302018-3rlya16w	34	46	sensitization	sensitization	NN
cord-302018-3rlya16w	34	47	is	be	VBZ
cord-302018-3rlya16w	34	48	not	not	RB
cord-302018-3rlya16w	34	49	addressed	address	VBN
cord-302018-3rlya16w	34	50	.	.	.
cord-302018-3rlya16w	35	1	For	for	IN
cord-302018-3rlya16w	35	2	patients	patient	NNS
cord-302018-3rlya16w	35	3	with	with	IN
cord-302018-3rlya16w	35	4	a	a	DT
cord-302018-3rlya16w	35	5	history	history	NN
cord-302018-3rlya16w	35	6	of	of	IN
cord-302018-3rlya16w	35	7	benign	benign	JJ
cord-302018-3rlya16w	35	8	cutaneous	cutaneous	JJ
cord-302018-3rlya16w	35	9	reactions	reaction	NNS
cord-302018-3rlya16w	35	10	,	,	,
cord-302018-3rlya16w	35	11	1	1	CD
cord-302018-3rlya16w	35	12	single	single	JJ
cord-302018-3rlya16w	35	13	oral	oral	JJ
cord-302018-3rlya16w	35	14	dose	dose	NN
cord-302018-3rlya16w	35	15	of	of	IN
cord-302018-3rlya16w	35	16	amoxicillin	amoxicillin	NNP
cord-302018-3rlya16w	35	17	is	be	VBZ
cord-302018-3rlya16w	35	18	recommended	recommend	VBN
cord-302018-3rlya16w	35	19	.	.	.
cord-302018-3rlya16w	36	1	What	what	WP
cord-302018-3rlya16w	36	2	are	be	VBP
cord-302018-3rlya16w	36	3	the	the	DT
cord-302018-3rlya16w	36	4	benefits	benefit	NNS
cord-302018-3rlya16w	36	5	and	and	CC
cord-302018-3rlya16w	36	6	dangers	danger	NNS
cord-302018-3rlya16w	36	7	of	of	IN
cord-302018-3rlya16w	36	8	a	a	DT
cord-302018-3rlya16w	36	9	drug	drug	NN
cord-302018-3rlya16w	36	10	allergy	allergy	NN
cord-302018-3rlya16w	36	11	label	label	NN
cord-302018-3rlya16w	36	12	?	?	.
cord-302018-3rlya16w	37	1	In	in	IN
cord-302018-3rlya16w	37	2	a	a	DT
cord-302018-3rlya16w	37	3	review	review	NN
cord-302018-3rlya16w	37	4	by	by	IN
cord-302018-3rlya16w	37	5	Solenki	Solenki	NNP
cord-302018-3rlya16w	37	6	,	,	,
cord-302018-3rlya16w	37	7	10	10	CD
cord-302018-3rlya16w	37	8	the	the	DT
cord-302018-3rlya16w	37	9	author	author	NN
cord-302018-3rlya16w	37	10	reviewed	review	VBD
cord-302018-3rlya16w	37	11	self	self	NN
cord-302018-3rlya16w	37	12	-	-	HYPH
cord-302018-3rlya16w	37	13	reported	report	VBN
cord-302018-3rlya16w	37	14	penicillin	penicillin	NN
cord-302018-3rlya16w	37	15	allergy	allergy	NN
cord-302018-3rlya16w	37	16	,	,	,
cord-302018-3rlya16w	37	17	which	which	WDT
cord-302018-3rlya16w	37	18	accounts	account	VBZ
cord-302018-3rlya16w	37	19	for	for	IN
cord-302018-3rlya16w	37	20	at	at	RB
cord-302018-3rlya16w	37	21	least	least	RBS
cord-302018-3rlya16w	37	22	10	10	CD
cord-302018-3rlya16w	37	23	%	%	NN
cord-302018-3rlya16w	37	24	of	of	IN
cord-302018-3rlya16w	37	25	the	the	DT
cord-302018-3rlya16w	37	26	population	population	NN
cord-302018-3rlya16w	37	27	,	,	,
cord-302018-3rlya16w	37	28	and	and	CC
cord-302018-3rlya16w	37	29	observed	observe	VBD
cord-302018-3rlya16w	37	30	that	that	IN
cord-302018-3rlya16w	37	31	,	,	,
cord-302018-3rlya16w	37	32	among	among	IN
cord-302018-3rlya16w	37	33	these	these	DT
cord-302018-3rlya16w	37	34	individuals	individual	NNS
cord-302018-3rlya16w	37	35	claiming	claim	VBG
cord-302018-3rlya16w	37	36	to	to	TO
cord-302018-3rlya16w	37	37	be	be	VB
cord-302018-3rlya16w	37	38	allergic	allergic	JJ
cord-302018-3rlya16w	37	39	to	to	IN
cord-302018-3rlya16w	37	40	penicillin	penicillin	NN
cord-302018-3rlya16w	37	41	,	,	,
cord-302018-3rlya16w	37	42	more	more	JJR
cord-302018-3rlya16w	37	43	than	than	IN
cord-302018-3rlya16w	37	44	90	90	CD
cord-302018-3rlya16w	37	45	%	%	NN
cord-302018-3rlya16w	37	46	are	be	VBP
cord-302018-3rlya16w	37	47	not	not	RB
cord-302018-3rlya16w	37	48	truly	truly	RB
cord-302018-3rlya16w	37	49	allergic	allergic	JJ
cord-302018-3rlya16w	37	50	and	and	CC
cord-302018-3rlya16w	37	51	can	can	MD
cord-302018-3rlya16w	37	52	tolerate	tolerate	VB
cord-302018-3rlya16w	37	53	penicillin	penicillin	NN
cord-302018-3rlya16w	37	54	.	.	.
cord-302018-3rlya16w	38	1	These	these	DT
cord-302018-3rlya16w	38	2	discrepancies	discrepancy	NNS
cord-302018-3rlya16w	38	3	were	be	VBD
cord-302018-3rlya16w	38	4	reviewed	review	VBN
cord-302018-3rlya16w	38	5	,	,	,
cord-302018-3rlya16w	38	6	which	which	WDT
cord-302018-3rlya16w	38	7	included	include	VBD
cord-302018-3rlya16w	38	8	initial	initial	JJ
cord-302018-3rlya16w	38	9	mislabeling	mislabeling	NN
cord-302018-3rlya16w	38	10	at	at	IN
cord-302018-3rlya16w	38	11	the	the	DT
cord-302018-3rlya16w	38	12	time	time	NN
cord-302018-3rlya16w	38	13	of	of	IN
cord-302018-3rlya16w	38	14	the	the	DT
cord-302018-3rlya16w	38	15	clinical	clinical	JJ
cord-302018-3rlya16w	38	16	event	event	NN
cord-302018-3rlya16w	38	17	,	,	,
cord-302018-3rlya16w	38	18	such	such	JJ
cord-302018-3rlya16w	38	19	as	as	IN
cord-302018-3rlya16w	38	20	associated	associate	VBN
cord-302018-3rlya16w	38	21	symptoms	symptom	NNS
cord-302018-3rlya16w	38	22	of	of	IN
cord-302018-3rlya16w	38	23	viral	viral	JJ
cord-302018-3rlya16w	38	24	infections	infection	NNS
cord-302018-3rlya16w	38	25	,	,	,
cord-302018-3rlya16w	38	26	including	include	VBG
cord-302018-3rlya16w	38	27	urticaria	urticaria	NN
cord-302018-3rlya16w	38	28	and	and	CC
cord-302018-3rlya16w	38	29	gastrointestinal	gastrointestinal	JJ
cord-302018-3rlya16w	38	30	adverse	adverse	JJ
cord-302018-3rlya16w	38	31	effects	effect	NNS
cord-302018-3rlya16w	38	32	of	of	IN
cord-302018-3rlya16w	38	33	antibiotics	antibiotic	NNS
cord-302018-3rlya16w	38	34	.	.	.
cord-302018-3rlya16w	39	1	Many	many	JJ
cord-302018-3rlya16w	39	2	drug	drug	NN
cord-302018-3rlya16w	39	3	allergies	allergy	NNS
cord-302018-3rlya16w	39	4	are	be	VBP
cord-302018-3rlya16w	39	5	not	not	RB
cord-302018-3rlya16w	39	6	long	long	RB
cord-302018-3rlya16w	39	7	-	-	HYPH
cord-302018-3rlya16w	39	8	lived	live	VBN
cord-302018-3rlya16w	39	9	and	and	CC
cord-302018-3rlya16w	39	10	the	the	DT
cord-302018-3rlya16w	39	11	natural	natural	JJ
cord-302018-3rlya16w	39	12	resolution	resolution	NN
cord-302018-3rlya16w	39	13	of	of	IN
cord-302018-3rlya16w	39	14	penicillin	penicillin	NN
cord-302018-3rlya16w	39	15	allergy	allergy	NN
cord-302018-3rlya16w	39	16	was	be	VBD
cord-302018-3rlya16w	39	17	reviewed	review	VBN
cord-302018-3rlya16w	39	18	.	.	.
cord-302018-3rlya16w	40	1	The	the	DT
cord-302018-3rlya16w	40	2	author	author	NN
cord-302018-3rlya16w	40	3	validated	validate	VBD
cord-302018-3rlya16w	40	4	current	current	JJ
cord-302018-3rlya16w	40	5	diagnostic	diagnostic	JJ
cord-302018-3rlya16w	40	6	tools	tool	NNS
cord-302018-3rlya16w	40	7	for	for	IN
cord-302018-3rlya16w	40	8	the	the	DT
cord-302018-3rlya16w	40	9	diagnosis	diagnosis	NN
cord-302018-3rlya16w	40	10	of	of	IN
cord-302018-3rlya16w	40	11	penicillin	penicillin	NN
cord-302018-3rlya16w	40	12	,	,	,
cord-302018-3rlya16w	40	13	cephalosporins	cephalosporin	NNS
cord-302018-3rlya16w	40	14	,	,	,
cord-302018-3rlya16w	40	15	and	and	CC
cord-302018-3rlya16w	40	16	other	other	JJ
cord-302018-3rlya16w	40	17	antibiotics	antibiotic	NNS
cord-302018-3rlya16w	40	18	allergies	allergy	NNS
cord-302018-3rlya16w	40	19	.	.	.
cord-302018-3rlya16w	41	1	Multicentered	multicentered	JJ
cord-302018-3rlya16w	41	2	clinical	clinical	JJ
cord-302018-3rlya16w	41	3	trials	trial	NNS
cord-302018-3rlya16w	41	4	are	be	VBP
cord-302018-3rlya16w	41	5	needed	need	VBN
cord-302018-3rlya16w	41	6	to	to	TO
cord-302018-3rlya16w	41	7	validate	validate	VB
cord-302018-3rlya16w	41	8	skin	skin	NN
cord-302018-3rlya16w	41	9	testing	testing	NN
cord-302018-3rlya16w	41	10	predictive	predictive	JJ
cord-302018-3rlya16w	41	11	values	value	NNS
cord-302018-3rlya16w	41	12	and	and	CC
cord-302018-3rlya16w	41	13	to	to	TO
cord-302018-3rlya16w	41	14	assess	assess	VB
cord-302018-3rlya16w	41	15	the	the	DT
cord-302018-3rlya16w	41	16	value	value	NN
cord-302018-3rlya16w	41	17	of	of	IN
cord-302018-3rlya16w	41	18	new	new	JJ
cord-302018-3rlya16w	41	19	tools	tool	NNS
cord-302018-3rlya16w	41	20	,	,	,
cord-302018-3rlya16w	41	21	such	such	JJ
cord-302018-3rlya16w	41	22	as	as	IN
cord-302018-3rlya16w	41	23	specific	specific	JJ
cord-302018-3rlya16w	41	24	immunoglobulin	immunoglobulin	NN
cord-302018-3rlya16w	41	25	E	e	NN
cord-302018-3rlya16w	41	26	and	and	CC
cord-302018-3rlya16w	41	27	basophil	basophil	NNP
cord-302018-3rlya16w	41	28	activation	activation	NN
cord-302018-3rlya16w	41	29	test	test	NN
cord-302018-3rlya16w	41	30	.	.	.
cord-302018-3rlya16w	42	1	How	how	WRB
cord-302018-3rlya16w	42	2	to	to	TO
cord-302018-3rlya16w	42	3	detect	detect	VB
cord-302018-3rlya16w	42	4	children	child	NNS
cord-302018-3rlya16w	42	5	with	with	IN
cord-302018-3rlya16w	42	6	true	true	JJ
cord-302018-3rlya16w	42	7	penicillin	penicillin	NN
cord-302018-3rlya16w	42	8	allergy	allergy	NN
cord-302018-3rlya16w	42	9	?	?	.
cord-302018-3rlya16w	43	1	Vyles	Vyles	NNP
cord-302018-3rlya16w	43	2	et	et	NNP
cord-302018-3rlya16w	43	3	al	al	NNP
cord-302018-3rlya16w	43	4	11	11	CD
cord-302018-3rlya16w	43	5	provide	provide	VBP
cord-302018-3rlya16w	43	6	a	a	DT
cord-302018-3rlya16w	43	7	review	review	NN
cord-302018-3rlya16w	43	8	that	that	WDT
cord-302018-3rlya16w	43	9	describes	describe	VBZ
cord-302018-3rlya16w	43	10	that	that	IN
cord-302018-3rlya16w	43	11	most	most	JJS
cord-302018-3rlya16w	43	12	allergies	allergy	NNS
cord-302018-3rlya16w	43	13	in	in	IN
cord-302018-3rlya16w	43	14	pediatric	pediatric	JJ
cord-302018-3rlya16w	43	15	patients	patient	NNS
cord-302018-3rlya16w	43	16	are	be	VBP
cord-302018-3rlya16w	43	17	self	self	NN
cord-302018-3rlya16w	43	18	-	-	HYPH
cord-302018-3rlya16w	43	19	reported	report	VBN
cord-302018-3rlya16w	43	20	and	and	CC
cord-302018-3rlya16w	43	21	often	often	RB
cord-302018-3rlya16w	43	22	clinically	clinically	RB
cord-302018-3rlya16w	43	23	inconsistent	inconsistent	JJ
cord-302018-3rlya16w	43	24	with	with	IN
cord-302018-3rlya16w	43	25	true	true	JJ
cord-302018-3rlya16w	43	26	allergy	allergy	NN
cord-302018-3rlya16w	43	27	.	.	.
cord-302018-3rlya16w	44	1	The	the	DT
cord-302018-3rlya16w	44	2	rate	rate	NN
cord-302018-3rlya16w	44	3	of	of	IN
cord-302018-3rlya16w	44	4	parent	parent	NN
cord-302018-3rlya16w	44	5	-	-	HYPH
cord-302018-3rlya16w	44	6	reported	report	VBN
cord-302018-3rlya16w	44	7	adverse	adverse	JJ
cord-302018-3rlya16w	44	8	drug	drug	NN
cord-302018-3rlya16w	44	9	reactions	reaction	NNS
cord-302018-3rlya16w	44	10	ranges	range	VBZ
cord-302018-3rlya16w	44	11	from	from	IN
cord-302018-3rlya16w	44	12	6	6	CD
cord-302018-3rlya16w	44	13	%	%	NN
cord-302018-3rlya16w	44	14	to	to	TO
cord-302018-3rlya16w	44	15	10	10	CD
cord-302018-3rlya16w	44	16	%	%	NN
cord-302018-3rlya16w	44	17	,	,	,
cord-302018-3rlya16w	44	18	and	and	CC
cord-302018-3rlya16w	44	19	most	most	JJS
cord-302018-3rlya16w	44	20	of	of	IN
cord-302018-3rlya16w	44	21	these	these	DT
cord-302018-3rlya16w	44	22	so	so	RB
cord-302018-3rlya16w	44	23	-	-	HYPH
cord-302018-3rlya16w	44	24	called	call	VBN
cord-302018-3rlya16w	44	25	allergic	allergic	JJ
cord-302018-3rlya16w	44	26	reactions	reaction	NNS
cord-302018-3rlya16w	44	27	are	be	VBP
cord-302018-3rlya16w	44	28	attributed	attribute	VBN
cord-302018-3rlya16w	44	29	to	to	IN
cord-302018-3rlya16w	44	30	beta	beta	NN
cord-302018-3rlya16w	44	31	-	-	HYPH
cord-302018-3rlya16w	44	32	lactam	lactam	NNS
cord-302018-3rlya16w	44	33	antibiotic	antibiotic	JJ
cord-302018-3rlya16w	44	34	derivatives	derivative	NNS
cord-302018-3rlya16w	44	35	,	,	,
cord-302018-3rlya16w	44	36	anti	anti	JJ
cord-302018-3rlya16w	44	37	-	-	JJ
cord-302018-3rlya16w	44	38	inflammatory	inflammatory	JJ
cord-302018-3rlya16w	44	39	drugs	drug	NNS
cord-302018-3rlya16w	44	40	,	,	,
cord-302018-3rlya16w	44	41	and	and	CC
cord-302018-3rlya16w	44	42	other	other	JJ
cord-302018-3rlya16w	44	43	antibiotics	antibiotic	NNS
cord-302018-3rlya16w	44	44	.	.	.
cord-302018-3rlya16w	45	1	Nonimmediate	Nonimmediate	NNP
cord-302018-3rlya16w	45	2	rashes	rash	NNS
cord-302018-3rlya16w	45	3	occurring	occur	VBG
cord-302018-3rlya16w	45	4	after	after	IN
cord-302018-3rlya16w	45	5	several	several	JJ
cord-302018-3rlya16w	45	6	days	day	NNS
cord-302018-3rlya16w	45	7	of	of	IN
cord-302018-3rlya16w	45	8	treatment	treatment	NN
cord-302018-3rlya16w	45	9	are	be	VBP
cord-302018-3rlya16w	45	10	the	the	DT
cord-302018-3rlya16w	45	11	most	most	RBS
cord-302018-3rlya16w	45	12	frequently	frequently	RB
cord-302018-3rlya16w	45	13	reported	report	VBN
cord-302018-3rlya16w	45	14	symptoms	symptom	NNS
cord-302018-3rlya16w	45	15	.	.	.
cord-302018-3rlya16w	46	1	Although	although	IN
cord-302018-3rlya16w	46	2	skin	skin	NN
cord-302018-3rlya16w	46	3	testing	testing	NN
cord-302018-3rlya16w	46	4	,	,	,
cord-302018-3rlya16w	46	5	followed	follow	VBN
cord-302018-3rlya16w	46	6	by	by	IN
cord-302018-3rlya16w	46	7	oral	oral	JJ
cord-302018-3rlya16w	46	8	challenge	challenge	NN
cord-302018-3rlya16w	46	9	,	,	,
cord-302018-3rlya16w	46	10	is	be	VBZ
cord-302018-3rlya16w	46	11	the	the	DT
cord-302018-3rlya16w	46	12	safest	safe	JJS
cord-302018-3rlya16w	46	13	way	way	NN
cord-302018-3rlya16w	46	14	to	to	TO
cord-302018-3rlya16w	46	15	identify	identify	VB
cord-302018-3rlya16w	46	16	true	true	JJ
cord-302018-3rlya16w	46	17	immunoglobulin	immunoglobulin	NN
cord-302018-3rlya16w	46	18	emediated	emediate	VBD
cord-302018-3rlya16w	46	19	allergy	allergy	NN
cord-302018-3rlya16w	46	20	in	in	IN
cord-302018-3rlya16w	46	21	children	child	NNS
cord-302018-3rlya16w	46	22	with	with	IN
cord-302018-3rlya16w	46	23	high	high	JJ
cord-302018-3rlya16w	46	24	-	-	HYPH
cord-302018-3rlya16w	46	25	risk	risk	NN
cord-302018-3rlya16w	46	26	allergy	allergy	NN
cord-302018-3rlya16w	46	27	symptoms	symptom	NNS
cord-302018-3rlya16w	46	28	,	,	,
cord-302018-3rlya16w	46	29	risk	risk	NN
cord-302018-3rlya16w	46	30	stratification	stratification	NN
cord-302018-3rlya16w	46	31	and	and	CC
cord-302018-3rlya16w	46	32	direct	direct	JJ
cord-302018-3rlya16w	46	33	oral	oral	JJ
cord-302018-3rlya16w	46	34	challenge	challenge	NN
cord-302018-3rlya16w	46	35	of	of	IN
cord-302018-3rlya16w	46	36	low	low	JJ
cord-302018-3rlya16w	46	37	-	-	HYPH
cord-302018-3rlya16w	46	38	risk	risk	NN
cord-302018-3rlya16w	46	39	patients	patient	NNS
cord-302018-3rlya16w	46	40	is	be	VBZ
cord-302018-3rlya16w	46	41	becoming	become	VBG
cord-302018-3rlya16w	46	42	a	a	DT
cord-302018-3rlya16w	46	43	standard	standard	NN
cord-302018-3rlya16w	46	44	.	.	.
cord-302018-3rlya16w	47	1	Of	of	IN
cord-302018-3rlya16w	47	2	interest	interest	NN
cord-302018-3rlya16w	47	3	are	be	VBP
cord-302018-3rlya16w	47	4	2	2	CD
cord-302018-3rlya16w	47	5	studies	study	NNS
cord-302018-3rlya16w	47	6	,	,	,
cord-302018-3rlya16w	47	7	which	which	WDT
cord-302018-3rlya16w	47	8	reported	report	VBD
cord-302018-3rlya16w	47	9	that	that	IN
cord-302018-3rlya16w	47	10	both	both	DT
cord-302018-3rlya16w	47	11	parents	parent	NNS
cord-302018-3rlya16w	47	12	and	and	CC
cord-302018-3rlya16w	47	13	physicians	physician	NNS
cord-302018-3rlya16w	47	14	were	be	VBD
cord-302018-3rlya16w	47	15	reluctant	reluctant	JJ
cord-302018-3rlya16w	47	16	to	to	TO
cord-302018-3rlya16w	47	17	utilize	utilize	VB
cord-302018-3rlya16w	47	18	penicillin	penicillin	NN
cord-302018-3rlya16w	47	19	class	class	NN
cord-302018-3rlya16w	47	20	antibiotics	antibiotic	NNS
cord-302018-3rlya16w	47	21	after	after	IN
cord-302018-3rlya16w	47	22	the	the	DT
cord-302018-3rlya16w	47	23	penicillin	penicillin	NNP
cord-302018-3rlya16w	47	24	allergy	allergy	NN
cord-302018-3rlya16w	47	25	label	label	NN
cord-302018-3rlya16w	47	26	was	be	VBD
cord-302018-3rlya16w	47	27	removed	remove	VBN
cord-302018-3rlya16w	47	28	because	because	IN
cord-302018-3rlya16w	47	29	of	of	IN
cord-302018-3rlya16w	47	30	fear	fear	NN
cord-302018-3rlya16w	47	31	of	of	IN
cord-302018-3rlya16w	47	32	an	an	DT
cord-302018-3rlya16w	47	33	allergic	allergic	JJ
cord-302018-3rlya16w	47	34	reaction	reaction	NN
cord-302018-3rlya16w	47	35	.	.	.
cord-302018-3rlya16w	48	1	The	the	DT
cord-302018-3rlya16w	48	2	authors	author	NNS
cord-302018-3rlya16w	48	3	concluded	conclude	VBD
cord-302018-3rlya16w	48	4	that	that	IN
cord-302018-3rlya16w	48	5	current	current	JJ
cord-302018-3rlya16w	48	6	and	and	CC
cord-302018-3rlya16w	48	7	future	future	JJ
cord-302018-3rlya16w	48	8	efforts	effort	NNS
cord-302018-3rlya16w	48	9	should	should	MD
cord-302018-3rlya16w	48	10	focus	focus	VB
cord-302018-3rlya16w	48	11	on	on	IN
cord-302018-3rlya16w	48	12	preventing	prevent	VBG
cord-302018-3rlya16w	48	13	penicillin	penicillin	NN
cord-302018-3rlya16w	48	14	allergy	allergy	NN
cord-302018-3rlya16w	48	15	labels	label	NNS
cord-302018-3rlya16w	48	16	that	that	WDT
cord-302018-3rlya16w	48	17	can	can	MD
cord-302018-3rlya16w	48	18	carry	carry	VB
cord-302018-3rlya16w	48	19	over	over	RP
cord-302018-3rlya16w	48	20	into	into	IN
cord-302018-3rlya16w	48	21	adulthood	adulthood	NN
cord-302018-3rlya16w	48	22	,	,	,
cord-302018-3rlya16w	48	23	providing	provide	VBG
cord-302018-3rlya16w	48	24	education	education	NN
cord-302018-3rlya16w	48	25	and	and	CC
cord-302018-3rlya16w	48	26	decision	decision	NN
cord-302018-3rlya16w	48	27	support	support	NN
cord-302018-3rlya16w	48	28	in	in	IN
cord-302018-3rlya16w	48	29	the	the	DT
cord-302018-3rlya16w	48	30	electronic	electronic	JJ
cord-302018-3rlya16w	48	31	medical	medical	JJ
cord-302018-3rlya16w	48	32	record	record	NN
cord-302018-3rlya16w	48	33	,	,	,
cord-302018-3rlya16w	48	34	and	and	CC
cord-302018-3rlya16w	48	35	testing	test	VBG
cord-302018-3rlya16w	48	36	low	low	JJ
cord-302018-3rlya16w	48	37	-	-	HYPH
cord-302018-3rlya16w	48	38	risk	risk	NN
cord-302018-3rlya16w	48	39	drug	drug	NN
cord-302018-3rlya16w	48	40	administration	administration	NN
cord-302018-3rlya16w	48	41	strategies	strategy	NNS
cord-302018-3rlya16w	48	42	in	in	IN
cord-302018-3rlya16w	48	43	low	low	JJ
cord-302018-3rlya16w	48	44	-	-	HYPH
cord-302018-3rlya16w	48	45	risk	risk	NN
cord-302018-3rlya16w	48	46	patients	patient	NNS
cord-302018-3rlya16w	48	47	.	.	.
cord-302018-3rlya16w	49	1	Integrating	integrate	VBG
cord-302018-3rlya16w	49	2	penicillin	penicillin	NNP
cord-302018-3rlya16w	49	3	allergy	allergy	NN
cord-302018-3rlya16w	49	4	management	management	NN
cord-302018-3rlya16w	49	5	into	into	IN
cord-302018-3rlya16w	49	6	stewardship	stewardship	NN
cord-302018-3rlya16w	49	7	efforts	effort	NNS
cord-302018-3rlya16w	49	8	with	with	IN
cord-302018-3rlya16w	49	9	the	the	DT
cord-302018-3rlya16w	49	10	government	government	NN
cord-302018-3rlya16w	49	11	and	and	CC
cord-302018-3rlya16w	49	12	third	third	JJ
cord-302018-3rlya16w	49	13	-	-	HYPH
cord-302018-3rlya16w	49	14	party	party	NN
cord-302018-3rlya16w	49	15	payer	payer	NN
cord-302018-3rlya16w	49	16	incentives	incentive	NNS
cord-302018-3rlya16w	49	17	should	should	MD
cord-302018-3rlya16w	49	18	be	be	VB
cord-302018-3rlya16w	49	19	the	the	DT
cord-302018-3rlya16w	49	20	long	long	JJ
cord-302018-3rlya16w	49	21	-	-	HYPH
cord-302018-3rlya16w	49	22	term	term	NN
cord-302018-3rlya16w	49	23	goal	goal	NN
cord-302018-3rlya16w	49	24	for	for	IN
cord-302018-3rlya16w	49	25	penicillin	penicillin	NN
cord-302018-3rlya16w	49	26	allergy	allergy	NN
cord-302018-3rlya16w	49	27	delabeling	delabeling	NN
cord-302018-3rlya16w	49	28	at	at	IN
cord-302018-3rlya16w	49	29	the	the	DT
cord-302018-3rlya16w	49	30	population	population	NN
cord-302018-3rlya16w	49	31	level	level	NN
cord-302018-3rlya16w	49	32	.	.	.
cord-302018-3rlya16w	50	1	What	what	WP
cord-302018-3rlya16w	50	2	is	be	VBZ
cord-302018-3rlya16w	50	3	the	the	DT
cord-302018-3rlya16w	50	4	current	current	JJ
cord-302018-3rlya16w	50	5	understanding	understanding	NN
cord-302018-3rlya16w	50	6	of	of	IN
cord-302018-3rlya16w	50	7	drug	drug	NN
cord-302018-3rlya16w	50	8	hypersensitivity	hypersensitivity	NN
cord-302018-3rlya16w	50	9	and	and	CC
cord-302018-3rlya16w	50	10	allergic	allergic	JJ
cord-302018-3rlya16w	50	11	reactions	reaction	NNS
cord-302018-3rlya16w	50	12	?	?	.
cord-302018-3rlya16w	51	1	Jakubovic	Jakubovic	NNP
cord-302018-3rlya16w	51	2	et	et	NNP
cord-302018-3rlya16w	51	3	al	al	NNP
cord-302018-3rlya16w	51	4	12	12	CD
cord-302018-3rlya16w	51	5	provide	provide	VBP
cord-302018-3rlya16w	51	6	a	a	DT
cord-302018-3rlya16w	51	7	broad	broad	JJ
cord-302018-3rlya16w	51	8	and	and	CC
cord-302018-3rlya16w	51	9	updated	updated	JJ
cord-302018-3rlya16w	51	10	review	review	NN
cord-302018-3rlya16w	51	11	of	of	IN
cord-302018-3rlya16w	51	12	the	the	DT
cord-302018-3rlya16w	51	13	current	current	JJ
cord-302018-3rlya16w	51	14	knowledge	knowledge	NN
cord-302018-3rlya16w	51	15	by	by	IN
cord-302018-3rlya16w	51	16	reviewing	review	VBG
cord-302018-3rlya16w	51	17	the	the	DT
cord-302018-3rlya16w	51	18	classical	classical	JJ
cord-302018-3rlya16w	51	19	model	model	NN
cord-302018-3rlya16w	51	20	of	of	IN
cord-302018-3rlya16w	51	21	drug	drug	NN
cord-302018-3rlya16w	51	22	hypersensitivity	hypersensitivity	NN
cord-302018-3rlya16w	51	23	reactions	reaction	NNS
cord-302018-3rlya16w	51	24	and	and	CC
cord-302018-3rlya16w	51	25	comparing	compare	VBG
cord-302018-3rlya16w	51	26	this	this	DT
cord-302018-3rlya16w	51	27	with	with	IN
cord-302018-3rlya16w	51	28	the	the	DT
cord-302018-3rlya16w	51	29	current	current	JJ
cord-302018-3rlya16w	51	30	and	and	CC
cord-302018-3rlya16w	51	31	more	more	RBR
cord-302018-3rlya16w	51	32	customized	customized	JJ
cord-302018-3rlya16w	51	33	classification	classification	NN
cord-302018-3rlya16w	51	34	based	base	VBN
cord-302018-3rlya16w	51	35	on	on	IN
cord-302018-3rlya16w	51	36	phenotypes	phenotype	NNS
cord-302018-3rlya16w	51	37	,	,	,
cord-302018-3rlya16w	51	38	endotypes	endotypes	NNP
cord-302018-3rlya16w	51	39	,	,	,
cord-302018-3rlya16w	51	40	and	and	CC
cord-302018-3rlya16w	51	41	biomarker	biomarker	NN
cord-302018-3rlya16w	51	42	profiles	profile	NNS
cord-302018-3rlya16w	51	43	.	.	.
cord-302018-3rlya16w	52	1	This	this	DT
cord-302018-3rlya16w	52	2	approach	approach	NN
cord-302018-3rlya16w	52	3	allows	allow	VBZ
cord-302018-3rlya16w	52	4	for	for	IN
cord-302018-3rlya16w	52	5	the	the	DT
cord-302018-3rlya16w	52	6	classification	classification	NN
cord-302018-3rlya16w	52	7	of	of	IN
cord-302018-3rlya16w	52	8	reactions	reaction	NNS
cord-302018-3rlya16w	52	9	to	to	IN
cord-302018-3rlya16w	52	10	chemotherapy	chemotherapy	NN
cord-302018-3rlya16w	52	11	drugs	drug	NNS
cord-302018-3rlya16w	52	12	,	,	,
cord-302018-3rlya16w	52	13	monoclonal	monoclonal	JJ
cord-302018-3rlya16w	52	14	antibodies	antibody	NNS
cord-302018-3rlya16w	52	15	,	,	,
cord-302018-3rlya16w	52	16	and	and	CC
cord-302018-3rlya16w	52	17	new	new	JJ
cord-302018-3rlya16w	52	18	small	small	JJ
cord-302018-3rlya16w	52	19	molecules	molecule	NNS
cord-302018-3rlya16w	52	20	.	.	.
cord-302018-3rlya16w	53	1	Complementing	complement	VBG
cord-302018-3rlya16w	53	2	the	the	DT
cord-302018-3rlya16w	53	3	Gell	Gell	NNP
cord-302018-3rlya16w	53	4	and	and	CC
cord-302018-3rlya16w	53	5	Coombs	Coombs	NNP
cord-302018-3rlya16w	53	6	classification	classification	NN
cord-302018-3rlya16w	53	7	drug	drug	NN
cord-302018-3rlya16w	53	8	allergy	allergy	NN
cord-302018-3rlya16w	53	9	phenotypes	phenotype	NNS
cord-302018-3rlya16w	53	10	allows	allow	VBZ
cord-302018-3rlya16w	53	11	for	for	IN
cord-302018-3rlya16w	53	12	the	the	DT
cord-302018-3rlya16w	53	13	description	description	NN
cord-302018-3rlya16w	53	14	of	of	IN
cord-302018-3rlya16w	53	15	classical	classical	JJ
cord-302018-3rlya16w	53	16	and	and	CC
cord-302018-3rlya16w	53	17	atypical	atypical	JJ
cord-302018-3rlya16w	53	18	clinical	clinical	JJ
cord-302018-3rlya16w	53	19	symptoms	symptom	NNS
cord-302018-3rlya16w	53	20	,	,	,
cord-302018-3rlya16w	53	21	such	such	JJ
cord-302018-3rlya16w	53	22	as	as	IN
cord-302018-3rlya16w	53	23	cytokine	cytokine	NN
cord-302018-3rlya16w	53	24	stormelike	stormelike	NN
cord-302018-3rlya16w	53	25	manifestations	manifestation	NNS
cord-302018-3rlya16w	53	26	in	in	IN
cord-302018-3rlya16w	53	27	the	the	DT
cord-302018-3rlya16w	53	28	context	context	NN
cord-302018-3rlya16w	53	29	of	of	IN
cord-302018-3rlya16w	53	30	drug	drug	NN
cord-302018-3rlya16w	53	31	exposure	exposure	NN
cord-302018-3rlya16w	53	32	,	,	,
cord-302018-3rlya16w	53	33	timing	timing	NN
cord-302018-3rlya16w	53	34	,	,	,
cord-302018-3rlya16w	53	35	and	and	CC
cord-302018-3rlya16w	53	36	severity	severity	NN
cord-302018-3rlya16w	53	37	.	.	.
cord-302018-3rlya16w	54	1	The	the	DT
cord-302018-3rlya16w	54	2	endotypes	endotype	NNS
cord-302018-3rlya16w	54	3	look	look	VBP
cord-302018-3rlya16w	54	4	at	at	IN
cord-302018-3rlya16w	54	5	the	the	DT
cord-302018-3rlya16w	54	6	mechanisms	mechanism	NNS
cord-302018-3rlya16w	54	7	,	,	,
cord-302018-3rlya16w	54	8	and	and	CC
cord-302018-3rlya16w	54	9	also	also	RB
cord-302018-3rlya16w	54	10	the	the	DT
cord-302018-3rlya16w	54	11	molecular	molecular	JJ
cord-302018-3rlya16w	54	12	and	and	CC
cord-302018-3rlya16w	54	13	cellular	cellular	JJ
cord-302018-3rlya16w	54	14	targets	target	NNS
cord-302018-3rlya16w	54	15	,	,	,
cord-302018-3rlya16w	54	16	whereas	whereas	IN
cord-302018-3rlya16w	54	17	biomarkers	biomarker	NNS
cord-302018-3rlya16w	54	18	are	be	VBP
cord-302018-3rlya16w	54	19	used	use	VBN
cord-302018-3rlya16w	54	20	as	as	IN
cord-302018-3rlya16w	54	21	diagnostic	diagnostic	JJ
cord-302018-3rlya16w	54	22	tools	tool	NNS
cord-302018-3rlya16w	54	23	.	.	.
cord-302018-3rlya16w	55	1	Biomarkers	biomarker	NNS
cord-302018-3rlya16w	55	2	such	such	JJ
cord-302018-3rlya16w	55	3	as	as	IN
cord-302018-3rlya16w	55	4	skin	skin	NN
cord-302018-3rlya16w	55	5	testing	testing	NN
cord-302018-3rlya16w	55	6	,	,	,
cord-302018-3rlya16w	55	7	tryptase	tryptase	NNP
cord-302018-3rlya16w	55	8	,	,	,
cord-302018-3rlya16w	55	9	and	and	CC
cord-302018-3rlya16w	55	10	basophil	basophil	NNP
cord-302018-3rlya16w	55	11	activation	activation	NN
cord-302018-3rlya16w	55	12	test	test	NN
cord-302018-3rlya16w	55	13	provide	provide	VBP
cord-302018-3rlya16w	55	14	the	the	DT
cord-302018-3rlya16w	55	15	signature	signature	NN
cord-302018-3rlya16w	55	16	for	for	IN
cord-302018-3rlya16w	55	17	the	the	DT
cord-302018-3rlya16w	55	18	different	different	JJ
cord-302018-3rlya16w	55	19	endotypes	endotype	NNS
cord-302018-3rlya16w	55	20	.	.	.
cord-302018-3rlya16w	56	1	As	as	IN
cord-302018-3rlya16w	56	2	more	more	JJR
cord-302018-3rlya16w	56	3	mechanisms	mechanism	NNS
cord-302018-3rlya16w	56	4	of	of	IN
cord-302018-3rlya16w	56	5	drug	drug	NN
cord-302018-3rlya16w	56	6	allergy	allergy	NN
cord-302018-3rlya16w	56	7	are	be	VBP
cord-302018-3rlya16w	56	8	uncovered	uncover	VBN
cord-302018-3rlya16w	56	9	and	and	CC
cord-302018-3rlya16w	56	10	new	new	JJ
cord-302018-3rlya16w	56	11	biomarkers	biomarker	NNS
cord-302018-3rlya16w	56	12	become	become	VBN
cord-302018-3rlya16w	56	13	available	available	JJ
cord-302018-3rlya16w	56	14	,	,	,
cord-302018-3rlya16w	56	15	they	-PRON-	PRP
cord-302018-3rlya16w	56	16	can	can	MD
cord-302018-3rlya16w	56	17	be	be	VB
cord-302018-3rlya16w	56	18	incorporated	incorporate	VBN
cord-302018-3rlya16w	56	19	into	into	IN
cord-302018-3rlya16w	56	20	this	this	DT
cord-302018-3rlya16w	56	21	flexible	flexible	JJ
cord-302018-3rlya16w	56	22	classification	classification	NN
cord-302018-3rlya16w	56	23	,	,	,
cord-302018-3rlya16w	56	24	guiding	guide	VBG
cord-302018-3rlya16w	56	25	clinicians	clinician	NNS
cord-302018-3rlya16w	56	26	toward	toward	IN
cord-302018-3rlya16w	56	27	an	an	DT
cord-302018-3rlya16w	56	28	optimal	optimal	JJ
cord-302018-3rlya16w	56	29	approach	approach	NN
cord-302018-3rlya16w	56	30	for	for	IN
cord-302018-3rlya16w	56	31	patient	patient	JJ
cord-302018-3rlya16w	56	32	labeling	labeling	NN
cord-302018-3rlya16w	56	33	or	or	CC
cord-302018-3rlya16w	56	34	delabeling	delabeling	NN
cord-302018-3rlya16w	56	35	,	,	,
cord-302018-3rlya16w	56	36	treatment	treatment	NN
cord-302018-3rlya16w	56	37	,	,	,
cord-302018-3rlya16w	56	38	and	and	CC
cord-302018-3rlya16w	56	39	management	management	NN
cord-302018-3rlya16w	56	40	.	.	.
cord-302018-3rlya16w	57	1	What	what	WP
cord-302018-3rlya16w	57	2	is	be	VBZ
cord-302018-3rlya16w	57	3	the	the	DT
cord-302018-3rlya16w	57	4	evidence	evidence	NN
cord-302018-3rlya16w	57	5	for	for	IN
cord-302018-3rlya16w	57	6	,	,	,
cord-302018-3rlya16w	57	7	and	and	CC
cord-302018-3rlya16w	57	8	how	how	WRB
cord-302018-3rlya16w	57	9	can	can	MD
cord-302018-3rlya16w	57	10	recommendations	recommendation	NNS
cord-302018-3rlya16w	57	11	be	be	VB
cord-302018-3rlya16w	57	12	made	make	VBN
cord-302018-3rlya16w	57	13	for	for	IN
cord-302018-3rlya16w	57	14	labeling	labeling	NN
cord-302018-3rlya16w	57	15	and	and	CC
cord-302018-3rlya16w	57	16	delabeling	delabeling	NN
cord-302018-3rlya16w	57	17	?	?	.
cord-302018-3rlya16w	58	1	Are	be	VBP
cord-302018-3rlya16w	58	2	there	there	EX
cord-302018-3rlya16w	58	3	models	model	NNS
cord-302018-3rlya16w	58	4	for	for	IN
cord-302018-3rlya16w	58	5	these	these	DT
cord-302018-3rlya16w	58	6	recommendations	recommendation	NNS
cord-302018-3rlya16w	58	7	?	?	.
cord-302018-3rlya16w	59	1	Shaker	Shaker	NNP
cord-302018-3rlya16w	59	2	et	et	NNP
cord-302018-3rlya16w	59	3	al	al	NNP
cord-302018-3rlya16w	59	4	,	,	,
cord-302018-3rlya16w	59	5	13	13	CD
cord-302018-3rlya16w	59	6	on	on	IN
cord-302018-3rlya16w	59	7	behalf	behalf	NN
cord-302018-3rlya16w	59	8	of	of	IN
cord-302018-3rlya16w	59	9	the	the	DT
cord-302018-3rlya16w	59	10	Joint	Joint	NNP
cord-302018-3rlya16w	59	11	Task	Task	NNP
cord-302018-3rlya16w	59	12	Force	Force	NNP
cord-302018-3rlya16w	59	13	for	for	IN
cord-302018-3rlya16w	59	14	Allergy	Allergy	NNP
cord-302018-3rlya16w	59	15	Practice	practice	NN
cord-302018-3rlya16w	59	16	Parameters	parameter	NNS
cord-302018-3rlya16w	59	17	(	(	-LRB-
cord-302018-3rlya16w	59	18	JTFPP	JTFPP	NNP
cord-302018-3rlya16w	59	19	)	)	-RRB-
cord-302018-3rlya16w	59	20	,	,	,
cord-302018-3rlya16w	59	21	provided	provide	VBD
cord-302018-3rlya16w	59	22	a	a	DT
cord-302018-3rlya16w	59	23	review	review	NN
cord-302018-3rlya16w	59	24	of	of	IN
cord-302018-3rlya16w	59	25	the	the	DT
cord-302018-3rlya16w	59	26	recommendations	recommendation	NNS
cord-302018-3rlya16w	59	27	for	for	IN
cord-302018-3rlya16w	59	28	anaphylaxis	anaphylaxis	NN
cord-302018-3rlya16w	59	29	treatment	treatment	NN
cord-302018-3rlya16w	59	30	.	.	.
cord-302018-3rlya16w	60	1	The	the	DT
cord-302018-3rlya16w	60	2	authors	author	NNS
cord-302018-3rlya16w	60	3	introduced	introduce	VBD
cord-302018-3rlya16w	60	4	Grading	Grading	NNP
cord-302018-3rlya16w	60	5	of	of	IN
cord-302018-3rlya16w	60	6	Recommendations	Recommendations	NNPS
cord-302018-3rlya16w	60	7	Assessment	Assessment	NNP
cord-302018-3rlya16w	60	8	,	,	,
cord-302018-3rlya16w	60	9	Development	Development	NNP
cord-302018-3rlya16w	60	10	,	,	,
cord-302018-3rlya16w	60	11	and	and	CC
cord-302018-3rlya16w	60	12	Evaluation	Evaluation	NNP
cord-302018-3rlya16w	60	13	(	(	-LRB-
cord-302018-3rlya16w	60	14	GRADE	GRADE	NNP
cord-302018-3rlya16w	60	15	)	)	-RRB-
cord-302018-3rlya16w	60	16	,	,	,
cord-302018-3rlya16w	60	17	a	a	DT
cord-302018-3rlya16w	60	18	new	new	JJ
cord-302018-3rlya16w	60	19	method	method	NN
cord-302018-3rlya16w	60	20	of	of	IN
cord-302018-3rlya16w	60	21	evidence	evidence	NN
cord-302018-3rlya16w	60	22	appraisal	appraisal	NN
cord-302018-3rlya16w	60	23	and	and	CC
cord-302018-3rlya16w	60	24	translation	translation	NN
cord-302018-3rlya16w	60	25	,	,	,
cord-302018-3rlya16w	60	26	which	which	WDT
cord-302018-3rlya16w	60	27	has	have	VBZ
cord-302018-3rlya16w	60	28	emerged	emerge	VBN
cord-302018-3rlya16w	60	29	as	as	IN
cord-302018-3rlya16w	60	30	a	a	DT
cord-302018-3rlya16w	60	31	leading	lead	VBG
cord-302018-3rlya16w	60	32	approach	approach	NN
cord-302018-3rlya16w	60	33	to	to	IN
cord-302018-3rlya16w	60	34	anaphylaxis	anaphylaxis	NN
cord-302018-3rlya16w	60	35	guidelines	guideline	NNS
cord-302018-3rlya16w	60	36	development	development	NN
cord-302018-3rlya16w	60	37	.	.	.
cord-302018-3rlya16w	61	1	GRADE	grade	NN
cord-302018-3rlya16w	61	2	creates	create	VBZ
cord-302018-3rlya16w	61	3	explicit	explicit	JJ
cord-302018-3rlya16w	61	4	processes	process	NNS
cord-302018-3rlya16w	61	5	for	for	IN
cord-302018-3rlya16w	61	6	evaluating	evaluate	VBG
cord-302018-3rlya16w	61	7	the	the	DT
cord-302018-3rlya16w	61	8	broad	broad	JJ
cord-302018-3rlya16w	61	9	evidence	evidence	NN
cord-302018-3rlya16w	61	10	based	base	VBN
cord-302018-3rlya16w	61	11	on	on	IN
cord-302018-3rlya16w	61	12	a	a	DT
cord-302018-3rlya16w	61	13	specific	specific	JJ
cord-302018-3rlya16w	61	14	,	,	,
cord-302018-3rlya16w	61	15	structured	structured	JJ
cord-302018-3rlya16w	61	16	,	,	,
cord-302018-3rlya16w	61	17	and	and	CC
cord-302018-3rlya16w	61	18	answerable	answerable	JJ
cord-302018-3rlya16w	61	19	clinical	clinical	JJ
cord-302018-3rlya16w	61	20	question	question	NN
cord-302018-3rlya16w	61	21	.	.	.
cord-302018-3rlya16w	62	1	Randomized	randomized	JJ
cord-302018-3rlya16w	62	2	controlled	control	VBN
cord-302018-3rlya16w	62	3	trials	trial	NNS
cord-302018-3rlya16w	62	4	begin	begin	VBP
cord-302018-3rlya16w	62	5	the	the	DT
cord-302018-3rlya16w	62	6	evaluation	evaluation	NN
cord-302018-3rlya16w	62	7	process	process	NN
cord-302018-3rlya16w	62	8	as	as	IN
cord-302018-3rlya16w	62	9	high	high	JJ
cord-302018-3rlya16w	62	10	certainty	certainty	NN
cord-302018-3rlya16w	62	11	,	,	,
cord-302018-3rlya16w	62	12	whereas	whereas	IN
cord-302018-3rlya16w	62	13	observational	observational	JJ
cord-302018-3rlya16w	62	14	studies	study	NNS
cord-302018-3rlya16w	62	15	begin	begin	VBP
cord-302018-3rlya16w	62	16	as	as	IN
cord-302018-3rlya16w	62	17	low	low	JJ
cord-302018-3rlya16w	62	18	certainty	certainty	NN
cord-302018-3rlya16w	62	19	.	.	.
cord-302018-3rlya16w	63	1	Evidence	evidence	NN
cord-302018-3rlya16w	63	2	may	may	MD
cord-302018-3rlya16w	63	3	be	be	VB
cord-302018-3rlya16w	63	4	downgraded	downgrade	VBN
cord-302018-3rlya16w	63	5	depending	depend	VBG
cord-302018-3rlya16w	63	6	on	on	IN
cord-302018-3rlya16w	63	7	the	the	DT
cord-302018-3rlya16w	63	8	following	follow	VBG
cord-302018-3rlya16w	63	9	considerations	consideration	NNS
cord-302018-3rlya16w	63	10	:	:	:
cord-302018-3rlya16w	63	11	(	(	-LRB-
cord-302018-3rlya16w	63	12	1	1	LS
cord-302018-3rlya16w	63	13	)	)	-RRB-
cord-302018-3rlya16w	63	14	the	the	DT
cord-302018-3rlya16w	63	15	risk	risk	NN
cord-302018-3rlya16w	63	16	of	of	IN
cord-302018-3rlya16w	63	17	bias	bias	NN
cord-302018-3rlya16w	63	18	,	,	,
cord-302018-3rlya16w	63	19	(	(	-LRB-
cord-302018-3rlya16w	63	20	2	2	LS
cord-302018-3rlya16w	63	21	)	)	-RRB-
cord-302018-3rlya16w	63	22	imprecision	imprecision	NN
cord-302018-3rlya16w	63	23	,	,	,
cord-302018-3rlya16w	63	24	(	(	-LRB-
cord-302018-3rlya16w	63	25	3	3	LS
cord-302018-3rlya16w	63	26	)	)	-RRB-
cord-302018-3rlya16w	63	27	inconsistency	inconsistency	NN
cord-302018-3rlya16w	63	28	,	,	,
cord-302018-3rlya16w	63	29	(	(	-LRB-
cord-302018-3rlya16w	63	30	4	4	LS
cord-302018-3rlya16w	63	31	)	)	-RRB-
cord-302018-3rlya16w	63	32	indirectness	indirectness	NN
cord-302018-3rlya16w	63	33	,	,	,
cord-302018-3rlya16w	63	34	and	and	CC
cord-302018-3rlya16w	63	35	(	(	-LRB-
cord-302018-3rlya16w	63	36	5	5	LS
cord-302018-3rlya16w	63	37	)	)	-RRB-
cord-302018-3rlya16w	63	38	publication	publication	NN
cord-302018-3rlya16w	63	39	bias	bias	NN
cord-302018-3rlya16w	63	40	.	.	.
cord-302018-3rlya16w	64	1	Through	through	IN
cord-302018-3rlya16w	64	2	this	this	DT
cord-302018-3rlya16w	64	3	methodology	methodology	NN
cord-302018-3rlya16w	64	4	,	,	,
cord-302018-3rlya16w	64	5	evidence	evidence	NN
cord-302018-3rlya16w	64	6	and	and	CC
cord-302018-3rlya16w	64	7	certainty	certainty	NN
cord-302018-3rlya16w	64	8	are	be	VBP
cord-302018-3rlya16w	64	9	clearly	clearly	RB
cord-302018-3rlya16w	64	10	and	and	CC
cord-302018-3rlya16w	64	11	simply	simply	RB
cord-302018-3rlya16w	64	12	described	describe	VBN
cord-302018-3rlya16w	64	13	as	as	IN
cord-302018-3rlya16w	64	14	"	"	``
cord-302018-3rlya16w	64	15	very	very	RB
cord-302018-3rlya16w	64	16	low	low	JJ
cord-302018-3rlya16w	64	17	,	,	,
cord-302018-3rlya16w	64	18	"	"	''
cord-302018-3rlya16w	64	19	"	"	``
cord-302018-3rlya16w	64	20	low	low	JJ
cord-302018-3rlya16w	64	21	,	,	,
cord-302018-3rlya16w	64	22	"	"	''
cord-302018-3rlya16w	64	23	"	"	``
cord-302018-3rlya16w	64	24	moderate	moderate	JJ
cord-302018-3rlya16w	64	25	,	,	,
cord-302018-3rlya16w	64	26	"	"	''
cord-302018-3rlya16w	64	27	or	or	CC
cord-302018-3rlya16w	64	28	"	"	``
cord-302018-3rlya16w	64	29	high	high	JJ
cord-302018-3rlya16w	64	30	.	.	.
cord-302018-3rlya16w	64	31	"	"	''
cord-302018-3rlya16w	65	1	The	the	DT
cord-302018-3rlya16w	65	2	JTFPP	JTFPP	NNP
cord-302018-3rlya16w	65	3	has	have	VBZ
cord-302018-3rlya16w	65	4	been	be	VBN
cord-302018-3rlya16w	65	5	producing	produce	VBG
cord-302018-3rlya16w	65	6	GRADE	grade	NN
cord-302018-3rlya16w	65	7	guidelines	guideline	NNS
cord-302018-3rlya16w	65	8	since	since	IN
cord-302018-3rlya16w	65	9	2017	2017	CD
cord-302018-3rlya16w	65	10	,	,	,
cord-302018-3rlya16w	65	11	and	and	CC
cord-302018-3rlya16w	65	12	the	the	DT
cord-302018-3rlya16w	65	13	2020	2020	CD
cord-302018-3rlya16w	65	14	JTFPP	JTFPP	NNP
cord-302018-3rlya16w	65	15	anaphylaxis	anaphylaxis	NN
cord-302018-3rlya16w	65	16	GRADE	grade	NN
cord-302018-3rlya16w	65	17	is	be	VBZ
cord-302018-3rlya16w	65	18	focused	focus	VBN
cord-302018-3rlya16w	65	19	on	on	IN
cord-302018-3rlya16w	65	20	the	the	DT
cord-302018-3rlya16w	65	21	practice	practice	NN
cord-302018-3rlya16w	65	22	of	of	IN
cord-302018-3rlya16w	65	23	anaphylaxis	anaphylaxis	NN
cord-302018-3rlya16w	65	24	prevention	prevention	NN
cord-302018-3rlya16w	65	25	through	through	IN
cord-302018-3rlya16w	65	26	identification	identification	NN
cord-302018-3rlya16w	65	27	and	and	CC
cord-302018-3rlya16w	65	28	mitigation	mitigation	NN
cord-302018-3rlya16w	65	29	of	of	IN
cord-302018-3rlya16w	65	30	risk	risk	NN
cord-302018-3rlya16w	65	31	factors	factor	NNS
cord-302018-3rlya16w	65	32	for	for	IN
cord-302018-3rlya16w	65	33	biphasic	biphasic	JJ
cord-302018-3rlya16w	65	34	anaphylaxis	anaphylaxis	NN
cord-302018-3rlya16w	65	35	and	and	CC
cord-302018-3rlya16w	65	36	evaluation	evaluation	NN
cord-302018-3rlya16w	65	37	of	of	IN
cord-302018-3rlya16w	65	38	the	the	DT
cord-302018-3rlya16w	65	39	use	use	NN
cord-302018-3rlya16w	65	40	of	of	IN
cord-302018-3rlya16w	65	41	supplemental	supplemental	JJ
cord-302018-3rlya16w	65	42	glucocorticoid	glucocorticoid	NN
cord-302018-3rlya16w	65	43	and/or	and/or	CC
cord-302018-3rlya16w	65	44	antihistamine	antihistamine	NN
cord-302018-3rlya16w	65	45	premedication	premedication	NN
cord-302018-3rlya16w	65	46	for	for	IN
cord-302018-3rlya16w	65	47	immunotherapy	immunotherapy	NN
cord-302018-3rlya16w	65	48	,	,	,
cord-302018-3rlya16w	65	49	radiocontrast	radiocontrast	NN
cord-302018-3rlya16w	65	50	media	medium	NNS
cord-302018-3rlya16w	65	51	and	and	CC
cord-302018-3rlya16w	65	52	chemotherapy	chemotherapy	NN
cord-302018-3rlya16w	65	53	.	.	.
cord-302018-3rlya16w	66	1	In	in	IN
cord-302018-3rlya16w	66	2	contrast	contrast	NN
cord-302018-3rlya16w	66	3	to	to	IN
cord-302018-3rlya16w	66	4	GRADE	grade	NN
cord-302018-3rlya16w	66	5	,	,	,
cord-302018-3rlya16w	66	6	Good	Good	NNP
cord-302018-3rlya16w	66	7	Practice	Practice	NNP
cord-302018-3rlya16w	66	8	Statements	statement	NNS
cord-302018-3rlya16w	66	9	include	include	VBP
cord-302018-3rlya16w	66	10	the	the	DT
cord-302018-3rlya16w	66	11	administration	administration	NN
cord-302018-3rlya16w	66	12	of	of	IN
cord-302018-3rlya16w	66	13	epinephrine	epinephrine	NN
cord-302018-3rlya16w	66	14	as	as	IN
cord-302018-3rlya16w	66	15	first	first	JJ
cord-302018-3rlya16w	66	16	-	-	HYPH
cord-302018-3rlya16w	66	17	line	line	NN
cord-302018-3rlya16w	66	18	treatment	treatment	NN
cord-302018-3rlya16w	66	19	for	for	IN
cord-302018-3rlya16w	66	20	uniphasic	uniphasic	NN
cord-302018-3rlya16w	66	21	and/or	and/or	CC
cord-302018-3rlya16w	66	22	biphasic	biphasic	JJ
cord-302018-3rlya16w	66	23	anaphylaxis	anaphylaxis	NN
cord-302018-3rlya16w	66	24	.	.	.
cord-302018-3rlya16w	67	1	A	a	DT
cord-302018-3rlya16w	67	2	good	good	JJ
cord-302018-3rlya16w	67	3	practice	practice	NN
cord-302018-3rlya16w	67	4	statement	statement	NN
cord-302018-3rlya16w	67	5	may	may	MD
cord-302018-3rlya16w	67	6	be	be	VB
cord-302018-3rlya16w	67	7	used	use	VBN
cord-302018-3rlya16w	67	8	when	when	WRB
cord-302018-3rlya16w	67	9	there	there	EX
cord-302018-3rlya16w	67	10	is	be	VBZ
cord-302018-3rlya16w	67	11	a	a	DT
cord-302018-3rlya16w	67	12	high	high	JJ
cord-302018-3rlya16w	67	13	certainty	certainty	NN
cord-302018-3rlya16w	67	14	that	that	IN
cord-302018-3rlya16w	67	15	a	a	DT
cord-302018-3rlya16w	67	16	recommendation	recommendation	NN
cord-302018-3rlya16w	67	17	will	will	MD
cord-302018-3rlya16w	67	18	be	be	VB
cord-302018-3rlya16w	67	19	more	more	RBR
cord-302018-3rlya16w	67	20	beneficial	beneficial	JJ
cord-302018-3rlya16w	67	21	than	than	IN
cord-302018-3rlya16w	67	22	harmful	harmful	JJ
cord-302018-3rlya16w	67	23	,	,	,
cord-302018-3rlya16w	67	24	though	though	IN
cord-302018-3rlya16w	67	25	there	there	EX
cord-302018-3rlya16w	67	26	is	be	VBZ
cord-302018-3rlya16w	67	27	little	little	JJ
cord-302018-3rlya16w	67	28	direct	direct	JJ
cord-302018-3rlya16w	67	29	evidence	evidence	NN
cord-302018-3rlya16w	67	30	.	.	.
cord-302018-3rlya16w	68	1	GRADE	grade	NN
cord-302018-3rlya16w	68	2	is	be	VBZ
cord-302018-3rlya16w	68	3	prescriptive	prescriptive	JJ
cord-302018-3rlya16w	68	4	,	,	,
cord-302018-3rlya16w	68	5	explicit	explicit	JJ
cord-302018-3rlya16w	68	6	,	,	,
cord-302018-3rlya16w	68	7	and	and	CC
cord-302018-3rlya16w	68	8	transparent	transparent	JJ
cord-302018-3rlya16w	68	9	and	and	CC
cord-302018-3rlya16w	68	10	requires	require	VBZ
cord-302018-3rlya16w	68	11	expert	expert	JJ
cord-302018-3rlya16w	68	12	judgment	judgment	NN
cord-302018-3rlya16w	68	13	and	and	CC
cord-302018-3rlya16w	68	14	consensus	consensus	NN
cord-302018-3rlya16w	68	15	of	of	IN
cord-302018-3rlya16w	68	16	guideline	guideline	NN
cord-302018-3rlya16w	68	17	groups	group	NNS
cord-302018-3rlya16w	68	18	as	as	IN
cord-302018-3rlya16w	68	19	evidence	evidence	NN
cord-302018-3rlya16w	68	20	is	be	VBZ
cord-302018-3rlya16w	68	21	evaluated	evaluate	VBN
cord-302018-3rlya16w	68	22	and	and	CC
cord-302018-3rlya16w	68	23	translated	translate	VBN
cord-302018-3rlya16w	68	24	into	into	IN
cord-302018-3rlya16w	68	25	recommendations	recommendation	NNS
cord-302018-3rlya16w	68	26	.	.	.
cord-302018-3rlya16w	69	1	What	what	WP
cord-302018-3rlya16w	69	2	is	be	VBZ
cord-302018-3rlya16w	69	3	the	the	DT
cord-302018-3rlya16w	69	4	practical	practical	JJ
cord-302018-3rlya16w	69	5	approach	approach	NN
cord-302018-3rlya16w	69	6	to	to	IN
cord-302018-3rlya16w	69	7	drug	drug	NN
cord-302018-3rlya16w	69	8	allergy	allergy	NN
cord-302018-3rlya16w	69	9	labeling	labeling	NN
cord-302018-3rlya16w	69	10	and	and	CC
cord-302018-3rlya16w	69	11	delabeling	delabeling	NN
cord-302018-3rlya16w	69	12	?	?	.
cord-302018-3rlya16w	70	1	Louisias	Louisias	NNP
cord-302018-3rlya16w	70	2	and	and	CC
cord-302018-3rlya16w	70	3	Wickner	Wickner	NNP
cord-302018-3rlya16w	70	4	14	14	CD
cord-302018-3rlya16w	70	5	provided	provide	VBD
cord-302018-3rlya16w	70	6	a	a	DT
cord-302018-3rlya16w	70	7	review	review	NN
cord-302018-3rlya16w	70	8	on	on	IN
cord-302018-3rlya16w	70	9	the	the	DT
cord-302018-3rlya16w	70	10	playground	playground	NN
cord-302018-3rlya16w	70	11	and	and	CC
cord-302018-3rlya16w	70	12	available	available	JJ
cord-302018-3rlya16w	70	13	tools	tool	NNS
cord-302018-3rlya16w	70	14	for	for	IN
cord-302018-3rlya16w	70	15	drug	drug	NN
cord-302018-3rlya16w	70	16	allergy	allergy	NN
cord-302018-3rlya16w	70	17	delabeling	delabeling	NN
cord-302018-3rlya16w	70	18	.	.	.
cord-302018-3rlya16w	71	1	The	the	DT
cord-302018-3rlya16w	71	2	authors	author	NNS
cord-302018-3rlya16w	71	3	indicated	indicate	VBD
cord-302018-3rlya16w	71	4	that	that	IN
cord-302018-3rlya16w	71	5	large	large	JJ
cord-302018-3rlya16w	71	6	-	-	HYPH
cord-302018-3rlya16w	71	7	scale	scale	NN
cord-302018-3rlya16w	71	8	drug	drug	NN
cord-302018-3rlya16w	71	9	allergy	allergy	NN
cord-302018-3rlya16w	71	10	delabeling	delabeling	NN
cord-302018-3rlya16w	71	11	is	be	VBZ
cord-302018-3rlya16w	71	12	influenced	influence	VBN
cord-302018-3rlya16w	71	13	by	by	IN
cord-302018-3rlya16w	71	14	multiple	multiple	JJ
cord-302018-3rlya16w	71	15	factors	factor	NNS
cord-302018-3rlya16w	71	16	,	,	,
cord-302018-3rlya16w	71	17	such	such	JJ
cord-302018-3rlya16w	71	18	as	as	IN
cord-302018-3rlya16w	71	19	changing	change	VBG
cord-302018-3rlya16w	71	20	cultural	cultural	JJ
cord-302018-3rlya16w	71	21	moors	moor	NNS
cord-302018-3rlya16w	71	22	,	,	,
cord-302018-3rlya16w	71	23	easily	easily	RB
cord-302018-3rlya16w	71	24	adapted	adapt	VBN
cord-302018-3rlya16w	71	25	tools	tool	NNS
cord-302018-3rlya16w	71	26	to	to	IN
cord-302018-3rlya16w	71	27	delabel	delabel	NN
cord-302018-3rlya16w	71	28	,	,	,
cord-302018-3rlya16w	71	29	and	and	CC
cord-302018-3rlya16w	71	30	electronic	electronic	JJ
cord-302018-3rlya16w	71	31	health	health	NN
cord-302018-3rlya16w	71	32	record	record	NN
cord-302018-3rlya16w	71	33	(	(	-LRB-
cord-302018-3rlya16w	71	34	EHR	EHR	NNP
cord-302018-3rlya16w	71	35	)	)	-RRB-
cord-302018-3rlya16w	71	36	crosstalk	crosstalk	NN
cord-302018-3rlya16w	71	37	.	.	.
cord-302018-3rlya16w	72	1	Current	current	JJ
cord-302018-3rlya16w	72	2	functionalities	functionality	NNS
cord-302018-3rlya16w	72	3	of	of	IN
cord-302018-3rlya16w	72	4	EHRs	ehr	NNS
cord-302018-3rlya16w	72	5	'	'	POS
cord-302018-3rlya16w	72	6	drug	drug	NN
cord-302018-3rlya16w	72	7	allergy	allergy	NN
cord-302018-3rlya16w	72	8	sections	section	NNS
cord-302018-3rlya16w	72	9	are	be	VBP
cord-302018-3rlya16w	72	10	often	often	RB
cord-302018-3rlya16w	72	11	at	at	IN
cord-302018-3rlya16w	72	12	odds	odd	NNS
cord-302018-3rlya16w	72	13	with	with	IN
cord-302018-3rlya16w	72	14	providing	provide	VBG
cord-302018-3rlya16w	72	15	reliable	reliable	JJ
cord-302018-3rlya16w	72	16	,	,	,
cord-302018-3rlya16w	72	17	updated	update	VBN
cord-302018-3rlya16w	72	18	,	,	,
cord-302018-3rlya16w	72	19	expert	expert	NN
cord-302018-3rlya16w	72	20	,	,	,
cord-302018-3rlya16w	72	21	safe	safe	JJ
cord-302018-3rlya16w	72	22	,	,	,
cord-302018-3rlya16w	72	23	and	and	CC
cord-302018-3rlya16w	72	24	affordable	affordable	JJ
cord-302018-3rlya16w	72	25	care	care	NN
cord-302018-3rlya16w	72	26	.	.	.
cord-302018-3rlya16w	73	1	They	-PRON-	PRP
cord-302018-3rlya16w	73	2	reported	report	VBD
cord-302018-3rlya16w	73	3	that	that	IN
cord-302018-3rlya16w	73	4	up	up	IN
cord-302018-3rlya16w	73	5	to	to	TO
cord-302018-3rlya16w	73	6	35	35	CD
cord-302018-3rlya16w	73	7	%	%	NN
cord-302018-3rlya16w	73	8	of	of	IN
cord-302018-3rlya16w	73	9	patients	patient	NNS
cord-302018-3rlya16w	73	10	had	have	VBD
cord-302018-3rlya16w	73	11	at	at	RB
cord-302018-3rlya16w	73	12	least	least	JJS
cord-302018-3rlya16w	73	13	1	1	CD
cord-302018-3rlya16w	73	14	drug	drug	NN
cord-302018-3rlya16w	73	15	allergy	allergy	NN
cord-302018-3rlya16w	73	16	listed	list	VBN
cord-302018-3rlya16w	73	17	in	in	IN
cord-302018-3rlya16w	73	18	their	-PRON-	PRP$
cord-302018-3rlya16w	73	19	EHR	EHR	NNP
cord-302018-3rlya16w	73	20	,	,	,
cord-302018-3rlya16w	73	21	and	and	CC
cord-302018-3rlya16w	73	22	many	many	JJ
cord-302018-3rlya16w	73	23	had	have	VBD
cord-302018-3rlya16w	73	24	up	up	IN
cord-302018-3rlya16w	73	25	to	to	TO
cord-302018-3rlya16w	73	26	20	20	CD
cord-302018-3rlya16w	73	27	;	;	:
cord-302018-3rlya16w	73	28	nobody	nobody	NN
cord-302018-3rlya16w	73	29	removed	remove	VBD
cord-302018-3rlya16w	73	30	duplicates	duplicate	NNS
cord-302018-3rlya16w	73	31	or	or	CC
cord-302018-3rlya16w	73	32	delabel	delabel	NN
cord-302018-3rlya16w	73	33	drugs	drug	NNS
cord-302018-3rlya16w	73	34	with	with	IN
cord-302018-3rlya16w	73	35	nonallergic	nonallergic	JJ
cord-302018-3rlya16w	73	36	symptoms	symptom	NNS
cord-302018-3rlya16w	73	37	.	.	.
cord-302018-3rlya16w	74	1	The	the	DT
cord-302018-3rlya16w	74	2	authors	author	NNS
cord-302018-3rlya16w	74	3	indicated	indicate	VBD
cord-302018-3rlya16w	74	4	the	the	DT
cord-302018-3rlya16w	74	5	need	need	NN
cord-302018-3rlya16w	74	6	to	to	TO
cord-302018-3rlya16w	74	7	uncover	uncover	VB
cord-302018-3rlya16w	74	8	the	the	DT
cord-302018-3rlya16w	74	9	integral	integral	JJ
cord-302018-3rlya16w	74	10	components	component	NNS
cord-302018-3rlya16w	74	11	of	of	IN
cord-302018-3rlya16w	74	12	drug	drug	NN
cord-302018-3rlya16w	74	13	allergy	allergy	NN
cord-302018-3rlya16w	74	14	delabeling	delabeling	NN
cord-302018-3rlya16w	74	15	programs	program	NNS
cord-302018-3rlya16w	74	16	that	that	WDT
cord-302018-3rlya16w	74	17	can	can	MD
cord-302018-3rlya16w	74	18	be	be	VB
cord-302018-3rlya16w	74	19	tailored	tailor	VBN
cord-302018-3rlya16w	74	20	and	and	CC
cord-302018-3rlya16w	74	21	disseminated	disseminate	VBN
cord-302018-3rlya16w	74	22	,	,	,
cord-302018-3rlya16w	74	23	incentivized	incentivize	VBN
cord-302018-3rlya16w	74	24	by	by	IN
cord-302018-3rlya16w	74	25	insurance	insurance	NN
cord-302018-3rlya16w	74	26	companies	company	NNS
cord-302018-3rlya16w	74	27	and	and	CC
cord-302018-3rlya16w	74	28	hospitals	hospital	NNS
cord-302018-3rlya16w	74	29	,	,	,
cord-302018-3rlya16w	74	30	and	and	CC
cord-302018-3rlya16w	74	31	standardized	standardize	VBD
cord-302018-3rlya16w	74	32	nationally	nationally	RB
cord-302018-3rlya16w	74	33	.	.	.
cord-302018-3rlya16w	75	1	One	one	CD
cord-302018-3rlya16w	75	2	study	study	NN
cord-302018-3rlya16w	75	3	estimated	estimate	VBD
cord-302018-3rlya16w	75	4	penicillin	penicillin	NN
cord-302018-3rlya16w	75	5	allergy	allergy	NN
cord-302018-3rlya16w	75	6	delabeling	delabeling	NNP
cord-302018-3rlya16w	75	7	programs	program	NNS
cord-302018-3rlya16w	75	8	could	could	MD
cord-302018-3rlya16w	75	9	have	have	VB
cord-302018-3rlya16w	75	10	cost	cost	NN
cord-302018-3rlya16w	75	11	savings	saving	NNS
cord-302018-3rlya16w	75	12	of	of	IN
cord-302018-3rlya16w	75	13	$	$	$
cord-302018-3rlya16w	75	14	192,223	192,223	CD
cord-302018-3rlya16w	75	15	per	per	IN
cord-302018-3rlya16w	75	16	year	year	NN
cord-302018-3rlya16w	75	17	in	in	IN
cord-302018-3rlya16w	75	18	tertiary	tertiary	JJ
cord-302018-3rlya16w	75	19	care	care	NN
cord-302018-3rlya16w	75	20	center	center	NN
cord-302018-3rlya16w	75	21	pediatric	pediatric	JJ
cord-302018-3rlya16w	75	22	emergency	emergency	NN
cord-302018-3rlya16w	75	23	departments	department	NNS
cord-302018-3rlya16w	75	24	,	,	,
cord-302018-3rlya16w	75	25	thus	thus	RB
cord-302018-3rlya16w	75	26	underscoring	underscore	VBG
cord-302018-3rlya16w	75	27	the	the	DT
cord-302018-3rlya16w	75	28	economic	economic	JJ
cord-302018-3rlya16w	75	29	incentives	incentive	NNS
cord-302018-3rlya16w	75	30	of	of	IN
cord-302018-3rlya16w	75	31	delabeling	delabeling	NN
cord-302018-3rlya16w	75	32	.	.	.
cord-302018-3rlya16w	76	1	Allergists	allergist	NNS
cord-302018-3rlya16w	76	2	need	need	VBP
cord-302018-3rlya16w	76	3	to	to	TO
cord-302018-3rlya16w	76	4	challenge	challenge	VB
cord-302018-3rlya16w	76	5	every	every	DT
cord-302018-3rlya16w	76	6	drug	drug	NN
cord-302018-3rlya16w	76	7	allergy	allergy	NN
cord-302018-3rlya16w	76	8	label	label	NN
cord-302018-3rlya16w	76	9	and	and	CC
cord-302018-3rlya16w	76	10	to	to	TO
cord-302018-3rlya16w	76	11	recognize	recognize	VB
cord-302018-3rlya16w	76	12	drug	drug	NN
cord-302018-3rlya16w	76	13	allergy	allergy	NN
cord-302018-3rlya16w	76	14	and	and	CC
cord-302018-3rlya16w	76	15	hypersensitivity	hypersensitivity	NN
cord-302018-3rlya16w	76	16	symptoms	symptom	NNS
cord-302018-3rlya16w	76	17	using	use	VBG
cord-302018-3rlya16w	76	18	the	the	DT
cord-302018-3rlya16w	76	19	new	new	JJ
cord-302018-3rlya16w	76	20	framework	framework	NN
cord-302018-3rlya16w	76	21	of	of	IN
cord-302018-3rlya16w	76	22	phenotypes	phenotype	NNS
cord-302018-3rlya16w	76	23	and	and	CC
cord-302018-3rlya16w	76	24	endotypes	endotype	NNS
cord-302018-3rlya16w	76	25	supported	support	VBN
cord-302018-3rlya16w	76	26	by	by	IN
cord-302018-3rlya16w	76	27	biomarkers	biomarker	NNS
cord-302018-3rlya16w	76	28	.	.	.
cord-302018-3rlya16w	77	1	Providing	provide	VBG
cord-302018-3rlya16w	77	2	risk	risk	NN
cord-302018-3rlya16w	77	3	stratification	stratification	NN
cord-302018-3rlya16w	77	4	is	be	VBZ
cord-302018-3rlya16w	77	5	key	key	JJ
cord-302018-3rlya16w	77	6	to	to	IN
cord-302018-3rlya16w	77	7	safe	safe	JJ
cord-302018-3rlya16w	77	8	delabeling	delabeling	NN
cord-302018-3rlya16w	77	9	procedures	procedure	NNS
cord-302018-3rlya16w	77	10	and	and	CC
cord-302018-3rlya16w	77	11	to	to	TO
cord-302018-3rlya16w	77	12	help	help	VB
cord-302018-3rlya16w	77	13	provide	provide	VB
cord-302018-3rlya16w	77	14	management	management	NN
cord-302018-3rlya16w	77	15	options	option	NNS
cord-302018-3rlya16w	77	16	including	include	VBG
cord-302018-3rlya16w	77	17	desensitization	desensitization	NN
cord-302018-3rlya16w	77	18	to	to	IN
cord-302018-3rlya16w	77	19	patients	patient	NNS
cord-302018-3rlya16w	77	20	who	who	WP
cord-302018-3rlya16w	77	21	are	be	VBP
cord-302018-3rlya16w	77	22	truly	truly	RB
cord-302018-3rlya16w	77	23	allergic	allergic	JJ
cord-302018-3rlya16w	77	24	.	.	.
cord-302018-3rlya16w	78	1	Minimizing	minimize	VBG
cord-302018-3rlya16w	78	2	inappropriate	inappropriate	JJ
cord-302018-3rlya16w	78	3	use	use	NN
cord-302018-3rlya16w	78	4	,	,	,
cord-302018-3rlya16w	78	5	recording	record	VBG
cord-302018-3rlya16w	78	6	accurate	accurate	JJ
cord-302018-3rlya16w	78	7	intolerances	intolerance	NNS
cord-302018-3rlya16w	78	8	,	,	,
cord-302018-3rlya16w	78	9	delabeling	delabele	VBG
cord-302018-3rlya16w	78	10	whenever	whenever	WRB
cord-302018-3rlya16w	78	11	possible	possible	JJ
cord-302018-3rlya16w	78	12	,	,	,
cord-302018-3rlya16w	78	13	and	and	CC
cord-302018-3rlya16w	78	14	adhering	adhere	VBG
cord-302018-3rlya16w	78	15	to	to	IN
cord-302018-3rlya16w	78	16	essential	essential	JJ
cord-302018-3rlya16w	78	17	elements	element	NNS
cord-302018-3rlya16w	78	18	of	of	IN
cord-302018-3rlya16w	78	19	effective	effective	JJ
cord-302018-3rlya16w	78	20	stewardship	stewardship	NN
cord-302018-3rlya16w	78	21	will	will	MD
cord-302018-3rlya16w	78	22	solve	solve	VB
cord-302018-3rlya16w	78	23	the	the	DT
cord-302018-3rlya16w	78	24	antibiotic	antibiotic	JJ
cord-302018-3rlya16w	78	25	allergy	allergy	NN
cord-302018-3rlya16w	78	26	epidemic	epidemic	NN
cord-302018-3rlya16w	78	27	.	.	.
cord-302018-3rlya16w	79	1	Renin	renin	NN
cord-302018-3rlya16w	79	2	-	-	HYPH
cord-302018-3rlya16w	79	3	angiotensin	angiotensin	NN
cord-302018-3rlya16w	79	4	-	-	HYPH
cord-302018-3rlya16w	79	5	aldosterone	aldosterone	NN
cord-302018-3rlya16w	79	6	system	system	NN
cord-302018-3rlya16w	79	7	inhibitors	inhibitor	NNS
cord-302018-3rlya16w	79	8	in	in	IN
cord-302018-3rlya16w	79	9	patients	patient	NNS
cord-302018-3rlya16w	79	10	with	with	IN
cord-302018-3rlya16w	79	11	COVID-19	COVID-19	NNP
cord-302018-3rlya16w	79	12	Coronavirus	Coronavirus	NNP
cord-302018-3rlya16w	79	13	disease	disease	NN
cord-302018-3rlya16w	79	14	2019	2019	CD
cord-302018-3rlya16w	79	15	(	(	-LRB-
cord-302018-3rlya16w	79	16	COVID-19	COVID-19	NNP
cord-302018-3rlya16w	79	17	)	)	-RRB-
cord-302018-3rlya16w	79	18	:	:	:
cord-302018-3rlya16w	79	19	epidemiology	epidemiology	NN
cord-302018-3rlya16w	79	20	,	,	,
cord-302018-3rlya16w	79	21	virology	virology	NN
cord-302018-3rlya16w	79	22	,	,	,
cord-302018-3rlya16w	79	23	clinical	clinical	JJ
cord-302018-3rlya16w	79	24	features	feature	NNS
cord-302018-3rlya16w	79	25	,	,	,
cord-302018-3rlya16w	79	26	diagnosis	diagnosis	NN
cord-302018-3rlya16w	79	27	,	,	,
cord-302018-3rlya16w	79	28	and	and	CC
cord-302018-3rlya16w	79	29	prevention	prevention	NN
cord-302018-3rlya16w	79	30	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-302018-3rlya16w	79	31	and	and	CC
cord-302018-3rlya16w	79	32	azithromycin	azithromycin	NNP
cord-302018-3rlya16w	79	33	as	as	IN
cord-302018-3rlya16w	79	34	a	a	DT
cord-302018-3rlya16w	79	35	treatment	treatment	NN
cord-302018-3rlya16w	79	36	of	of	IN
cord-302018-3rlya16w	79	37	COVID-19	covid-19	NN
cord-302018-3rlya16w	79	38	:	:	:
cord-302018-3rlya16w	79	39	results	result	NNS
cord-302018-3rlya16w	79	40	of	of	IN
cord-302018-3rlya16w	79	41	an	an	DT
cord-302018-3rlya16w	79	42	open	open	JJ
cord-302018-3rlya16w	79	43	-	-	HYPH
cord-302018-3rlya16w	79	44	label	label	NN
cord-302018-3rlya16w	79	45	non	non	JJ
cord-302018-3rlya16w	79	46	-	-	JJ
cord-302018-3rlya16w	79	47	randomized	randomized	JJ
cord-302018-3rlya16w	79	48	clinical	clinical	JJ
cord-302018-3rlya16w	79	49	trial	trial	NN
cord-302018-3rlya16w	79	50	NIH	NIH	NNP
cord-302018-3rlya16w	79	51	clinical	clinical	JJ
cord-302018-3rlya16w	79	52	trial	trial	NN
cord-302018-3rlya16w	79	53	of	of	IN
cord-302018-3rlya16w	79	54	remdesivir	remdesivir	NNP
cord-302018-3rlya16w	79	55	to	to	TO
cord-302018-3rlya16w	79	56	treat	treat	VB
cord-302018-3rlya16w	79	57	COVID-19	COVID-19	NNP
cord-302018-3rlya16w	80	1	begins	begin	VBZ
cord-302018-3rlya16w	80	2	:	:	:
cord-302018-3rlya16w	80	3	study	study	VB
cord-302018-3rlya16w	80	4	enrolling	enrol	VBG
cord-302018-3rlya16w	80	5	hospitalized	hospitalize	VBN
cord-302018-3rlya16w	80	6	adults	adult	NNS
cord-302018-3rlya16w	80	7	with	with	IN
cord-302018-3rlya16w	80	8	COVID-19	covid-19	CD
cord-302018-3rlya16w	80	9	in	in	IN
cord-302018-3rlya16w	80	10	Nebraska	Nebraska	NNP
cord-302018-3rlya16w	80	11	Tocilizumab	Tocilizumab	NNP
cord-302018-3rlya16w	80	12	in	in	IN
cord-302018-3rlya16w	80	13	COVID-19	COVID-19	NNP
cord-302018-3rlya16w	80	14	pneumonia	pneumonia	NN
cord-302018-3rlya16w	80	15	(	(	-LRB-
cord-302018-3rlya16w	80	16	TOCIVID-19	tocivid-19	CD
cord-302018-3rlya16w	80	17	)	)	-RRB-
cord-302018-3rlya16w	80	18	Penicillin	penicillin	NN
cord-302018-3rlya16w	80	19	allergy	allergy	NN
cord-302018-3rlya16w	80	20	Diagnosis	diagnosis	NN
cord-302018-3rlya16w	80	21	and	and	CC
cord-302018-3rlya16w	80	22	management	management	NN
cord-302018-3rlya16w	80	23	of	of	IN
cord-302018-3rlya16w	80	24	anaphylaxis	anaphylaxis	NN
cord-302018-3rlya16w	80	25	in	in	IN
cord-302018-3rlya16w	80	26	precision	precision	NN
cord-302018-3rlya16w	80	27	medicine	medicine	NN
cord-302018-3rlya16w	80	28	Hypersensitivity	hypersensitivity	NN
cord-302018-3rlya16w	80	29	reactions	reaction	NNS
cord-302018-3rlya16w	80	30	to	to	IN
cord-302018-3rlya16w	80	31	therapeutic	therapeutic	JJ
cord-302018-3rlya16w	80	32	monoclonal	monoclonal	JJ
cord-302018-3rlya16w	80	33	antibodies	antibody	NNS
cord-302018-3rlya16w	80	34	:	:	:
cord-302018-3rlya16w	80	35	phenotypes	phenotype	NNS
cord-302018-3rlya16w	80	36	and	and	CC
cord-302018-3rlya16w	80	37	endotypes	endotypes	NNP
cord-302018-3rlya16w	81	1	Addressing	address	VBG
cord-302018-3rlya16w	81	2	the	the	DT
cord-302018-3rlya16w	81	3	epidemic	epidemic	NN
cord-302018-3rlya16w	81	4	of	of	IN
cord-302018-3rlya16w	81	5	antibiotic	antibiotic	JJ
cord-302018-3rlya16w	81	6	"	"	``
cord-302018-3rlya16w	81	7	allergy	allergy	NN
cord-302018-3rlya16w	81	8	"	"	''
cord-302018-3rlya16w	81	9	over	over	IN
cord-302018-3rlya16w	81	10	-	-	HYPH
cord-302018-3rlya16w	81	11	diagnosis	diagnosis	NN
cord-302018-3rlya16w	81	12	Doctor	doctor	NN
cord-302018-3rlya16w	81	13	,	,	,
cord-302018-3rlya16w	81	14	I	-PRON-	PRP
cord-302018-3rlya16w	81	15	am	be	VBP
cord-302018-3rlya16w	81	16	allergic	allergic	JJ
cord-302018-3rlya16w	81	17	to	to	IN
cord-302018-3rlya16w	81	18	penicillin	penicillin	NN
cord-302018-3rlya16w	81	19	Children	child	NNS
cord-302018-3rlya16w	81	20	with	with	IN
cord-302018-3rlya16w	81	21	reported	report	VBN
cord-302018-3rlya16w	81	22	penicillin	penicillin	NN
cord-302018-3rlya16w	81	23	allergy	allergy	NN
cord-302018-3rlya16w	81	24	:	:	:
cord-302018-3rlya16w	81	25	public	public	JJ
cord-302018-3rlya16w	81	26	health	health	NN
cord-302018-3rlya16w	81	27	impact	impact	NN
cord-302018-3rlya16w	81	28	and	and	CC
cord-302018-3rlya16w	81	29	safety	safety	NN
cord-302018-3rlya16w	81	30	of	of	IN
cord-302018-3rlya16w	81	31	delabeling	delabele	VBG
cord-302018-3rlya16w	81	32	Drug	Drug	NNP
cord-302018-3rlya16w	81	33	hypersensitivity	hypersensitivity	NN
cord-302018-3rlya16w	81	34	in	in	IN
cord-302018-3rlya16w	81	35	the	the	DT
cord-302018-3rlya16w	81	36	fast	fast	JJ
cord-302018-3rlya16w	81	37	lane	lane	NN
cord-302018-3rlya16w	81	38	:	:	:
cord-302018-3rlya16w	82	1	what	what	WP
cord-302018-3rlya16w	82	2	clinicians	clinician	NNS
cord-302018-3rlya16w	82	3	should	should	MD
cord-302018-3rlya16w	82	4	know	know	VB
cord-302018-3rlya16w	82	5	about	about	IN
cord-302018-3rlya16w	82	6	phenotypes	phenotype	NNS
cord-302018-3rlya16w	82	7	,	,	,
cord-302018-3rlya16w	82	8	endotypes	endotypes	NNP
cord-302018-3rlya16w	82	9	,	,	,
cord-302018-3rlya16w	82	10	and	and	CC
cord-302018-3rlya16w	82	11	biomarker	biomarker	NN
cord-302018-3rlya16w	82	12	Making	make	VBG
cord-302018-3rlya16w	82	13	the	the	DT
cord-302018-3rlya16w	82	14	GRADE	grade	NN
cord-302018-3rlya16w	82	15	in	in	IN
cord-302018-3rlya16w	82	16	anaphylaxis	anaphylaxis	NN
cord-302018-3rlya16w	82	17	management	management	NN
cord-302018-3rlya16w	82	18	:	:	:
cord-302018-3rlya16w	82	19	toward	toward	IN
cord-302018-3rlya16w	82	20	recommendations	recommendation	NNS
cord-302018-3rlya16w	82	21	integrating	integrate	VBG
cord-302018-3rlya16w	82	22	values	value	NNS
cord-302018-3rlya16w	82	23	,	,	,
cord-302018-3rlya16w	82	24	preferences	preference	NNS
cord-302018-3rlya16w	82	25	,	,	,
cord-302018-3rlya16w	82	26	context	context	NN
cord-302018-3rlya16w	82	27	,	,	,
cord-302018-3rlya16w	82	28	and	and	CC
cord-302018-3rlya16w	82	29	shared	share	VBN
cord-302018-3rlya16w	82	30	decision	decision	NN
cord-302018-3rlya16w	82	31	making	make	VBG
cord-302018-3rlya16w	82	32	Drug	Drug	NNP
cord-302018-3rlya16w	82	33	allergy	allergy	NN
cord-302018-3rlya16w	82	34	delabeling	delabeling	NN
cord-302018-3rlya16w	82	35	in	in	IN
cord-302018-3rlya16w	82	36	the	the	DT
cord-302018-3rlya16w	82	37	clinical	clinical	JJ
cord-302018-3rlya16w	82	38	setting	setting	NN
cord-302018-3rlya16w	82	39	:	:	:
cord-302018-3rlya16w	82	40	an	an	DT
cord-302018-3rlya16w	82	41	all	all	RB
cord-302018-3rlya16w	82	42	-	-	HYPH
cord-302018-3rlya16w	82	43	handson	handson	JJ
cord-302018-3rlya16w	82	44	-	-	HYPH
cord-302018-3rlya16w	82	45	deck	deck	NN
cord-302018-3rlya16w	82	46	opportunity	opportunity	NN
cord-302018-3rlya16w	82	47	Division	Division	NNP
cord-302018-3rlya16w	82	48	of	of	IN
cord-302018-3rlya16w	82	49	Rheumatology	Rheumatology	NNP
cord-302018-3rlya16w	82	50	,	,	,
cord-302018-3rlya16w	82	51	Immunology	Immunology	NNP
cord-302018-3rlya16w	82	52	,	,	,
cord-302018-3rlya16w	82	53	and	and	CC
cord-302018-3rlya16w	82	54	AllergyBrigham	AllergyBrigham	NNP
cord-302018-3rlya16w	82	55	and	and	CC
cord-302018-3rlya16w	82	56	Women	Women	NNP
cord-302018-3rlya16w	82	57	's	's	POS
cord-302018-3rlya16w	82	58	Hospital	Hospital	NNP
cord-302018-3rlya16w	82	59	Boston	Boston	NNP
cord-302018-3rlya16w	82	60	,	,	,
cord-302018-3rlya16w	82	61	Massachusetts	Massachusetts	NNP
cord-302018-3rlya16w	82	62	mcastells@bwh.harvard.edu	mcastells@bwh.harvard.edu	NNP